<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN">
  <front>
    <journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="publisher">pmed</journal-id><journal-id journal-id-type="flc">plme</journal-id><journal-id journal-id-type="nlm-ta">PLoS Med</journal-id><journal-id journal-id-type="pmc">plosmed</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Medicine</journal-title></journal-title-group><issn pub-type="ppub">1549-1277</issn><issn pub-type="epub">1549-1676</issn><publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher></journal-meta>
    <article-meta><article-id pub-id-type="doi">10.1371/journal.pmed.0030467</article-id><article-id pub-id-type="publisher-id">06-PLME-RA-0381R2</article-id><article-id pub-id-type="sici">plme-03-12-11</article-id><article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Genetics and Genomics</subject>
          <subject>Oncology</subject>
          <subject>Oncology</subject>
        </subj-group>
        <subj-group subj-group-type="System Taxonomy">
          <subject>Oncology</subject>
          <subject>Cancer: lung</subject>
          <subject>Genetics</subject>
        </subj-group>
      </article-categories><title-group><article-title>A Gene Expression Signature Predicts Survival of Patients with Stage I
          Non-Small Cell Lung Cancer</article-title><alt-title alt-title-type="running-head">Gene Expression Profiles and Lung
        Cancer</alt-title></title-group><contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Lu</surname>
            <given-names>Yan</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Lemon</surname>
            <given-names>William</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Liu</surname>
            <given-names>Peng-Yuan</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Yi</surname>
            <given-names>Yijun</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Morrison</surname>
            <given-names>Carl</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Yang</surname>
            <given-names>Ping</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Sun</surname>
            <given-names>Zhifu</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Szoke</surname>
            <given-names>Janos</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Gerald</surname>
            <given-names>William L</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Watson</surname>
            <given-names>Mark</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff6">
            <sup>6</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Govindan</surname>
            <given-names>Ramaswamy</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff7">
            <sup>7</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>You</surname>
            <given-names>Ming</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
      </contrib-group><aff id="aff1">
        <label>1</label>
        <addr-line>Department of Surgery, Washington University School of Medicine, St. Louis,
          Missouri, United States of America </addr-line>
      </aff><aff id="aff2">
        <label>2</label>
        <addr-line>The Alvin J. Siteman Cancer Center, Washington University School of Medicine, St.
          Louis, Missouri, United States of America </addr-line>
      </aff><aff id="aff3">
        <label>3</label>
        <addr-line>Department of Pathology, The Ohio State University Comprehensive Cancer Center,
          Columbus, Ohio, United States of America </addr-line>
      </aff><aff id="aff4">
        <label>4</label>
        <addr-line>Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United
          States of America </addr-line>
      </aff><aff id="aff5">
        <label>5</label>
        <addr-line>Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New
          York, United States of America </addr-line>
      </aff><aff id="aff6">
        <label>6</label>
        <addr-line>Department of Pathology and Immunology, Washington University in St. Louis, St.
          Louis, Missouri, United States of America </addr-line>
      </aff><aff id="aff7">
        <label>7</label>
        <addr-line>Department of Internal Medicine, Washington University in St. Louis, St. Louis,
          Missouri, United States of America </addr-line>
      </aff><contrib-group>
        <contrib contrib-type="editor" xlink:type="simple">
          <name name-style="western">
            <surname>Kaminski</surname>
            <given-names>Naftali</given-names>
          </name>
          <role>Academic Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group><aff id="edit1">University of Pittsburgh School of Medicine, United States of America</aff><author-notes>
        <fn fn-type="con" id="ack1">
          <p>YL and MY designed the study. YL, WL, YY, PYL, and MY analyzed the data. ZS and RG
            enrolled patients. YL, PYL, YY, PY, MW, RG, and MY contributed to writing the paper. YL
            conducted statistical analyses and collected data from different institutes. YY and CM
            performed immunohistochemistry experiments and data analysis. ZS collected patient
            clinical information and did microarray experiments for the data from Mayo Clinic. MW
            designed, generated, and coordinated analysis of one of the datasets used in this
          study.</p>
        </fn>
        <corresp id="cor1">* To whom correspondence should be addressed. E-mail: <email xlink:type="simple">youm@msnotes.wustl.edu</email></corresp>
      <fn fn-type="conflict" id="n102">
        <p> The authors have declared that no competing interests exist.</p>
      </fn></author-notes><pub-date pub-type="ppub">
        <month>12</month>
        <year>2006</year>
      </pub-date><pub-date pub-type="epub">
        <day>26</day>
        <month>12</month>
        <year>2006</year>
      </pub-date><volume>3</volume><issue>12</issue><elocation-id>e467</elocation-id><history>
        <date date-type="received">
          <day>16</day>
          <month>5</month>
          <year>2006</year>
        </date>
        <date date-type="accepted">
          <day>20</day>
          <month>9</month>
          <year>2006</year>
        </date>
      </history><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2006</copyright-year><copyright-holder>Lu et al</copyright-holder><license><license-p>This is an open-access article distributed under the terms of
        the Creative Commons Attribution License, which permits unrestricted use, distribution, and
        reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract>
        <sec id="st1">
          <title>Background</title>
          <p>Lung cancer is the leading cause of cancer-related death in the United States. Nearly
            50% of patients with stages I and II non-small cell lung cancer (NSCLC) will
            die from recurrent disease despite surgical resection. No reliable clinical or molecular
            predictors are currently available for identifying those at high risk for developing
            recurrent disease. As a consequence, it is not possible to select those high-risk
            patients for more aggressive therapies and assign less aggressive treatments to patients
            at low risk for recurrence.</p>
        </sec>
        <sec id="st2">
          <title>Methods and Findings</title>
          <p>In this study, we applied a meta-analysis of datasets from seven different microarray
            studies on NSCLC for differentially expressed genes related to survival time (under 2 y
            and over 5 y). A consensus set of 4,905 genes from these studies was selected, and
            systematic bias adjustment in the datasets was performed by distance-weighted
            discrimination (DWD). We identified a gene expression signature consisting of 64 genes
            that is highly predictive of which stage I lung cancer patients may benefit from more
            aggressive therapy. Kaplan-Meier analysis of the overall survival of stage I NSCLC
            patients with the 64-gene expression signature demonstrated that the high- and low-risk
            groups are significantly different in their overall survival. Of the 64 genes, 11 are
            related to cancer metastasis <italic>(APC, CDH8, IL8RB, LY6D, PCDHGA12, DSP, NID, ENPP2,
              CCR2, CASP8,</italic> and <italic>CASP10)</italic> and eight are involved in apoptosis
              <italic>(CASP8, CASP10, PIK3R1, BCL2, SON, INHA, PSEN1,</italic> and
            <italic>BIK)</italic>.</p>
        </sec>
        <sec id="st3">
          <title>Conclusions</title>
          <p>Our results indicate that gene expression signatures from several datasets can be
            reconciled. The resulting signature is useful in predicting survival of stage I NSCLC
            and might be useful in informing treatment decisions.</p>
        </sec>
      </abstract><abstract abstract-type="toc">
        <p>Meta-analysis of several lung cancer gene expression studies yields a set of 64 genes
          whose expression profile is useful in predicting survival of patients with early-stage
          lung cancer and possibly informing treatment decisions.</p>
      </abstract><abstract abstract-type="editor">
        <title>Editors' Summary</title>
        <sec id="sb1">
          <title/>
          <sec id="sb1a">
            <title>Background.</title>
            <p>Lung cancer is the commonest cause of cancer-related death worldwide. Most cases are
              of a type called non-small cell lung cancer (NSCLC) and are mainly caused by smoking.
              Like other cancers, how NSCLC is treated depends on the “stage” at
              which it is detected. Stage IA NSCLCs are small and confined to the lung and can be
              removed surgically; patients with slightly larger stage IB tumors often receive
              chemotherapy after surgery. In stage II NSCLC, cancer cells may be present in lymph
              nodes near the tumor. Surgery plus chemotherapy is the usual treatment for this stage
              and for some stage III NSCLCs. However, in this stage, the tumor can be present
              throughout the chest and surgery is not always possible. For such cases and in stage
              IV NSCLC, where the tumor has spread throughout the body, patients are treated with
              chemotherapy alone. The stage at which NSCLC is detected also determines how well
              patients respond to treatment. Those who can be treated surgically do much better than
              those who can't. So, whereas only 2% of patients with stage IV lung cancer
              survive for 5 years after diagnosis, about 70% of patients with stage I or
              II lung cancer live at least this long.</p>
          </sec>
          <sec id="sb1b">
            <title>Why Was This Study Done?</title>
            <p>Even stage I and II lung cancers often recur and there is no accurate way to identify
              the patients in which this will happen. If there was, these patients could be given
              aggressive chemotherapy, so the search is on for a “molecular
              signature” to help identify which NSCLCs are likely to recur. Unlike normal
              cells, cancer cells divide uncontrollably and can move around the body. These
              behavioral differences are caused by changes in their genetic material that alter
              their patterns of RNA transcription and protein expression. In this study, the
              researchers have investigated whether data from several microarray studies (a
              technique used to catalog the genes expressed in cells) can be pooled to construct a
              gene expression signature that predicts the survival of patients with stage I
            NSCLC.</p>
          </sec>
          <sec id="sb1c">
            <title>What Did the Researchers Do and Find?</title>
            <p>The researchers took the data from seven independent microarray studies (including a
              new study of their own) that recorded gene expression profiles related to survival
              time (less than 2 years and greater than 5 years) for stage I NSCLC. Because these
              studies had been done in different places with slightly different techniques, the
              researchers applied a statistical tool called distance-weighted discrimination to
              smooth out any systematic differences among the studies before identifying 64 genes
              whose expression was associated with survival. Most of these genes are involved in
              cell adhesion, cell motility, cell proliferation, and cell death, all processes that
              are altered in cancer cells. The researchers then developed a statistical model that
              allowed them to use the gene expression and survival data to calculate risk scores for
              nearly 200 patients in five of the datasets. When they separated the patients into
              high and low risk groups on the basis of these scores, the two groups were
              significantly different in terms of survival time. Indeed, the gene expression
              signature was better at predicting outcome than routine staging. Finally, the
              researchers validated the gene expression signature by showing that it predicted
              survival with more than 85% accuracy in two independent datasets.</p>
          </sec>
          <sec id="sb1d">
            <title>What Do These Findings Mean?</title>
            <p>The 64 gene expression signature identified here could help clinicians prepare
              treatment plans for patients with stage I NSCLC. Because it accurately predicts
              survival in patients with adenocarcinoma or squamous cell cancer (the two major
              subtypes of NSCLC), it potentially indicates which of these patients should receive
              aggressive chemotherapy and which can be spared this unpleasant treatment. Previous
              attempts to establish gene expression signatures to predict outcome have used data
              from small groups of patients and have failed when tested in additional patients. In
              contrast, this new signature seems to be generalizable. Nevertheless, its ability to
              predict outcomes must be confirmed in further studies before it is routinely adopted
              by oncologists for treatment planning.</p>
          </sec>
          <sec id="sb1e">
            <title>Additional Information.</title>
            <p>Please access these Web sites via the online version of this summary at <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pmed.0030467" xlink:type="simple">http://dx.doi.org/10.1371/journal.pmed.0030467</ext-link>.</p>
            <list list-type="bullet">
              <list-item>
                <p><ext-link ext-link-type="uri" xlink:href="http://www.cancer.gov/cancertopics/types/lung" xlink:type="simple">US National Cancer
                    Institute</ext-link> information on lung cancer for patients and health
                  professionals.</p>
              </list-item>
              <list-item>
                <p><ext-link ext-link-type="uri" xlink:href="http://www.nlm.nih.gov/medlineplus/ency/article/007194.htm" xlink:type="simple">MedlinePlus</ext-link> encyclopedia entries on small-cell and non-small-cell
                  lung cancer.</p>
              </list-item>
              <list-item>
                <p><ext-link ext-link-type="uri" xlink:href="http://www.cancerhelp.org.uk/help/default.asp?page=2787" xlink:type="simple">Cancer
                    Research UK</ext-link>, information on patients about all aspects of lung
                  cancer.</p>
              </list-item>
              <list-item>
                <p>Wikipedia pages on <ext-link ext-link-type="uri" xlink:href="http://en.wikipedia.org/wiki/DNA_microarray" xlink:type="simple">DNA
                  microarrays</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://en.wikipedia.org/wiki/Expression_profiling" xlink:type="simple">expression
                    profiling</ext-link> (note that Wikipedia is a free online encyclopedia that
                  anyone can edit).</p>
              </list-item>
            </list>
          </sec>
        </sec>
      </abstract><funding-group><funding-statement>This work was supported by grants from the US National Institutes of Health (CA058554,
          CA093643, CA099187, ES012063, ES013340, and CA084354). The funders had no role in study
          design, data collection and analysis, decision to publish, or preparation of the
          manuscript.</funding-statement></funding-group><counts>
        <page-count count="15"/>
      </counts><!--===== Restructure custom-meta-wrap to custom-meta-group =====--><custom-meta-group>
        <custom-meta>
          <meta-name>citation</meta-name>
          <meta-value>Lu Y, Lemon W, Liu PY, Yi Y, Morrison C, et al. (2006) A gene expression
            signature predicts survival of patients with stage I non-small cell lung cancer. PLoS
            Med 3(12): e467. doi:<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1371/journal.pmed.0030467" xlink:type="simple">10.1371/journal.pmed.0030467</ext-link></meta-value>
        </custom-meta>
      </custom-meta-group></article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>Lung cancer is the leading cause of cancer death for both men and women in the US
          [<xref ref-type="bibr" rid="pmed-0030467-b001">1</xref>]. The high
        mortality among patients with lung cancer is mainly due to the absence of an effective
        screening strategy to identify lung cancer at an early stage [<xref ref-type="bibr" rid="pmed-0030467-b002">2</xref>]. Thus, only ~25% of patients
        presenting with lung cancer are in a sufficiently early stage to be amenable to effective
        surgical treatment. Patients with stage I or II non-small cell lung cancer (NSCLC) have
        ~70% five-year survival after surgery alone compared to less than a 5%
        five-year survival for advanced lung cancer (stages IIIB and IV) [<xref ref-type="bibr" rid="pmed-0030467-b003">3</xref>]. Even with surgical resection,
        almost half of those with stage I or II disease eventually die from recurrences.</p>
      <p>Treatment choices for patients with NSCLC depend on the stage at which the cancer is
        diagnosed. Patients diagnosed with stage I NSCLC usually receive surgical resection only
          [<xref ref-type="bibr" rid="pmed-0030467-b004">4</xref>]. Patients with
        stage IA (T1N0M0) undergo resection and are rarely treated with adjuvant chemotherapy.
        Patients with resected stage IB–III (any T any N M0 except T1N0M0) NSCLC show
        improved survival when given adjuvant chemotherapy [<xref ref-type="bibr" rid="pmed-0030467-b004">4</xref>].</p>
      <p>No reliable clinical or molecular predictors of recurrent disease are currently available.
        Because of heterogeneity in recurrence rates among patients with the same stage of cancer,
        it is critical to isolate a reliable molecular signature in tumors that could be used to
        identify those who are likely to develop recurrent disease and would thus benefit from
        adjuvant therapy. Moreover, identification of genes and molecular pathways critical for
        development of metastasis could lead to advances in therapeutics.</p>
      <p>Several studies based on microarray technology have been performed to determine genetic
        profiles predictive of survival in NSCLC and to develop genomic approaches for stratifying
        risk [<xref ref-type="bibr" rid="pmed-0030467-b005">5</xref>–<xref ref-type="bibr" rid="pmed-0030467-b008">8</xref>]. However, the identified
        survival-related genes lacked consistency among these studies, likely due to limited patient
        samples, disease heterogeneity, and/or technical factors such as differences in microarray
        platforms and specimen processing. In this study, we conducted a meta-analysis of seven
        datasets to search for differentially expressed genes related to survival time (under 2
        years, i.e., short-term survival and over 5 years, i.e., long-term survival). The data
        analyzed include our own previously unpublished dataset.</p>
    </sec>
    <sec id="s2" sec-type="methods">
      <title>Methods</title>
      <sec id="s2a">
        <title>Data Collection</title>
        <sec id="s2a1">
          <title>Samples from Washington University.</title>
          <p>Thirty-six patients who underwent resection of stage IB NSCLC at Washington University
            School of Medicine (WUSM; St. Louis, Missouri, United States) were recruited for this
            study. These samples are referred to as dataset 1. Informed consent was obtained from
            the patients for tissue procurement prior to surgery and their medical records were
            maintained according to institutional guidelines and in conformance with HIPPA
            regulations. The overall survival data on all patients were censored on the date of the
            last follow-up visit or death from causes other than lung cancer. Tumor tissues were
            processed by the Human Tissue Bank and the Gene Chip Facility at WUSM according to
            standard operating procedures and protocols.</p>
          <p>Briefly, frozen tissue samples at −80°C were pulverized and total
            cellular RNA was collected from each flash-frozen sample using TRIzol RNA isolation
            reagent (Invitrogen [<ext-link ext-link-type="uri" xlink:href="http://www.invitrogen.com" xlink:type="simple">http://www.invitrogen.com</ext-link>]). Total RNA was processed with a Qiagen
              (<ext-link ext-link-type="uri" xlink:href="http://www.qiagen.com" xlink:type="simple">http://www.qiagen.com</ext-link>) RNeasy Mini kit. In vitro transcription-based RNA
            amplification was then performed on at least 8 μg of total RNA from each sample.
            Complementary DNA was synthesized using the T7-(dT)24 primer:
            5′-GGCCAGTGAATTGTAATACGACT-CACTATAGGGAGGCGG-(dT)24–3′. The
            cDNA was processed using phase-lock gel (Fisher [<ext-link ext-link-type="uri" xlink:href="http://www.fishersci.com" xlink:type="simple">http://www.fishersci.com</ext-link>;
            #E0032005101]) phenol/chloroform extraction. Next, in vitro
            transcriptional labeling with biotin was performed using the Enzo Bioarray Kit
            (Affymetrix [<ext-link ext-link-type="uri" xlink:href="http://www.affymetrix.com" xlink:type="simple">http://www.affymetrix.com</ext-link>;
            #900182]). The resulting cRNA was processed again using the Qiagen
            RNeasy Mini kit. Labeled cRNA was hybridized to HG_U95Av2 (Affymetrix) arrays according
            to manufacturer's instructions.</p>
          <p>The raw fluorescence intensity data within CEL files were preprocessed with Robust
            Multichip Average (RMA) algorithm [<xref ref-type="bibr" rid="pmed-0030467-b009">9</xref>], as implemented with R packages from
            Bioconductor (<ext-link ext-link-type="uri" xlink:href="http://www.bioconductor.org" xlink:type="simple">http://www.bioconductor.org</ext-link>). This algorithm analyzes the microarray data
            in three steps: a background adjustment, quantile normalization, and finally summation
            of the probe intensities for each probe set using a log scale linear additive model for
            the log transform of (background corrected, normalized) PM intensities.</p>
        </sec>
        <sec id="s2a2">
          <title>Samples from Mayo Clinic.</title>
          <p>Eighteen patients with stage I squamous cell carcinoma (SCC) were selected from the
            patients diagnosed with lung cancer from 1997 to 2001 who underwent resection at Mayo
            Clinic, Rochester, Minnesota, United States. These samples are referred to as dataset 2.
            All enrolled patients and use of their tissues in the study were approved by the
            institutional review board of Mayo Clinic. The resected tumors were flash-frozen to
            −80 °C within 30 min after the tissues were surgically removed. The
            RNA isolation, cRNA synthesis, and microarray hybridization were performed as described
            by Sun et al. [<xref ref-type="bibr" rid="pmed-0030467-b006">6</xref>]. The raw fluorescence intensity data within CEL files were also
            preprocessed with the RMA algorithm.</p>
        </sec>
        <sec id="s2a3">
          <title>Samples from other groups.</title>
          <p>Dataset 3 was from Beer et al. [<xref ref-type="bibr" rid="pmed-0030467-b005">5</xref>] and includes 67 stage I primary lung adenocarcinomas (ADCs)
              (<ext-link ext-link-type="uri" xlink:href="http://dot.ped.med.umich.edu:2000/ourimage/pub/Lung/index.html" xlink:type="simple">http://dot.ped.med.umich.edu:2000/ourimage/pub/Lung/index.html</ext-link>). Dataset 4
            was from Bhattacharjee et al. [<xref ref-type="bibr" rid="pmed-0030467-b010">10</xref>] and includes 72 stage I lung ADCs (<ext-link ext-link-type="uri" xlink:href="http://www.broad.mit.edu/mpr/lung/" xlink:type="simple">http://www.broad.mit.edu/mpr/lung/</ext-link>). Dataset 5 was from Borczuk et al.
              [<xref ref-type="bibr" rid="pmed-0030467-b008">8</xref>] and
            includes one squamous and three ADCs (<ext-link ext-link-type="uri" xlink:href="http://hora.cpmc.columbia.edu/dept/pulmonary/5ResearchPages/Laboratories/powell%20supp1.htm" xlink:type="simple">http://hora.cpmc.columbia.edu/dept/pulmonary/5ResearchPages/Laboratories/powell%20supp1.htm</ext-link>).
            Dataset 6 was from Gerald et al. (unpublished data) and includes 63 stage I lung ADCs.
            Dataset 7 was from Bild et al. [<xref ref-type="bibr" rid="pmed-0030467-b011">11</xref>] and includes 33 squamous cell carcinomas and 31 ADCs (GEO
            accession number GSE3141). The raw data within the CEL files of these datasets were also
            preprocessed with the RMA algorithm.</p>
          <p>All the samples used in our data analyses are listed in <xref ref-type="supplementary-material" rid="pmed-0030467-st001">Table S1</xref>. Details of
            the clinical information for the subjects in each dataset are described in <xref ref-type="table" rid="pmed-0030467-t001">Table 1</xref>.</p>
          <table-wrap content-type="2col" id="pmed-0030467-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.0030467.t001</object-id><label>Table 1</label><caption>
              <p>Clinical Summary of Patients in the Analyzed Datasets</p>
            </caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.0030467.t001" xlink:type="simple"/><!-- <table frame="hsides" rules="none"><colgroup><col id="tb1col1" align="left" charoff="0" char=""/><col id="tb1col2" align="left" charoff="0" char=""/><col id="tb1col3" align="left" charoff="0" char=""/><col id="tb1col4" align="left" charoff="0" char=""/><col id="tb1col5" align="left" charoff="0" char=""/><col id="tb1col6" align="left" charoff="0" char=""/><col id="tb1col7" align="left" charoff="0" char=""/><col id="tb1col8" align="left" charoff="0" char=""/><col id="tb1col9" align="left" charoff="0" char=""/></colgroup><thead><tr><td align="left"><hr/>Characteristics</td><td><hr/>Measurements</td><td><hr/>Dataset 1</td><td><hr/>Dataset 2</td><td><hr/>Dataset 3</td><td><hr/>Dataset 4</td><td><hr/>Dataset 5</td><td><hr/>Dataset 6</td><td><hr/>Dataset 7</td></tr></thead><tbody><tr><td>Total samples</td><td><italic>n</italic></td><td>36</td><td>18</td><td>67</td><td>4</td><td>72</td><td>63</td><td>64</td></tr><tr><td>Mean age (range)</td><td>Years</td><td>66 (48&ndash;81)</td><td>70 (59&ndash;80)</td><td>64 (41&ndash;85)</td><td>76 (61&ndash;88)</td><td>64 (33&ndash;88)</td><td>65 (40&ndash;82)</td><td>ND</td></tr><tr><td>Sex</td><td>Male</td><td>20</td><td>10</td><td>25</td><td>2</td><td>29</td><td>27</td><td>ND</td></tr><tr><td></td><td>Female</td><td>16</td><td>8</td><td>42</td><td>2</td><td>43</td><td>36</td><td>ND</td></tr><tr><td>Mean follow-up (days)</td><td>Total overall survival</td><td>1,369</td><td>1,301</td><td>1,310</td><td>303</td><td>1,403</td><td>1,387</td><td>1,139</td></tr><tr><td></td><td>Total alive</td><td>1,570</td><td>1,813</td><td>1,430</td><td>303</td><td>1,805</td><td>1,441</td><td>1,414</td></tr><tr><td></td><td>Total dead</td><td>665</td><td>660</td><td>924</td><td>ND</td><td>901</td><td>1,064</td><td>785</td></tr><tr><td>Stage</td><td>IA</td><td>0</td><td>7</td><td>44</td><td>1</td><td>33</td><td>25</td><td>30</td></tr><tr><td></td><td>IB</td><td>36</td><td>11</td><td>23</td><td>3</td><td>39</td><td>38</td><td>27</td></tr><tr><td>Histological type</td><td>ADC</td><td>14</td><td>0</td><td>67</td><td>3</td><td>72</td><td>63</td><td>31</td></tr><tr><td></td><td>SCC</td><td>18</td><td>18</td><td>0</td><td>1</td><td>0</td><td>0</td><td>33</td></tr><tr><td></td><td>Other</td><td>4</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr></tbody></table> --><!-- <table-wrap-foot><fn id="nt101"><p>ND, no data</p></fn></table-wrap-foot> --></table-wrap>
        </sec>
      </sec>
      <sec id="s2b">
        <title>Data Processing</title>
        <sec id="s2b1">
          <title>Gene matching.</title>
          <p>Because several different microarray platforms were used in these datasets, the probe
            sets should be matched to identical genes. The batch query tool provided by Affymetrix
              (<ext-link ext-link-type="uri" xlink:href="https://www.affymetrix.com/analysis/netaffx/batch_query.affx" xlink:type="simple">https://www.affymetrix.com/analysis/netaffx/batch_query.affx</ext-link>) was used for
            matching probe sets among datasets 1 to 7 [<xref ref-type="bibr" rid="pmed-0030467-b012">12</xref>]. Based on the latest UniGene clusters
            annotation provided by the manufacturer (NCBI Build 35.1), there were a total of 4,905
            genes on all the five Affymetrix microarray systems HG_U95Av2, Hu6800, Hu133A,
            HG_U133AB, and Hu133plus2.</p>
        </sec>
        <sec id="s2b2">
          <title>Distance-weighted discrimination.</title>
          <p>Systematic differences from different datasets were remarkable, which would compromise
            the integrity of the data from different laboratories. To integrate the gene expression
            data from datasets 1 to 5, the distance-weighted discrimination (DWD) method (<ext-link ext-link-type="uri" xlink:href="https://genome.unc.edu/pubsup/dwd/index.html" xlink:type="simple">https://genome.unc.edu/pubsup/dwd/index.html</ext-link>) [<xref ref-type="bibr" rid="pmed-0030467-b013">13</xref>] was used to identify and
            adjust systematic differences that were present within these microarray datasets. The
            DWD method corrects for systematic biases across microarray batches by finding a
            separating hyperplane between the two batches and adjusting the data by projecting the
            different batches on the DWD plane, finding the batch mean, and then subtracting out the
            DWD plane multiplied by this mean [<xref ref-type="bibr" rid="pmed-0030467-b013">13</xref>]. All of the 197 samples from the five
            datasets were broken into two sub-branches, each of which was composed of samples from
            all of the five datasets (<xref ref-type="supplementary-material" rid="pmed-0030467-sg001">Figure S1</xref>). Poolability tests were performed to
            examine if these DWD-transformed gene expression data from different resources were
            poolable [<xref ref-type="bibr" rid="pmed-0030467-b014">14</xref>]. We
            randomly reshuffled data resources and generated 100 replicates of simulated data. We
            then compared the number of <italic>p</italic>-values below certain thresholds with the
            expected counts obtained by simulations that take into account the distributions of the
            DWD-transformed gene expression data and sample size in our study.</p>
        </sec>
      </sec>
      <sec id="s2c">
        <title>Data Analysis</title>
        <p>To preselect survival-related genes, ANOVA analysis was applied to 88 patients in
          datasets 1 to 5 who died within 2 years or survived beyond 5 years after surgery.
          Empirical <italic>p</italic>-values for each gene were obtained through 10,000 permutation
          tests. Genes with significant survival effects (<italic>p</italic> &lt; 0.01) were
          selected for Cox proportional hazards regression analyses. Multivariate Cox proportional
          hazards regression analyses (adjusted for age, gender, cancer subtype, and cancer stage)
          with 10,000 bootstrap resampling were performed for each survival-related gene using all
          of 197 samples in datasets 1 to 5. The proportional hazards assumption for variables such
          as age, sex, cancer subtype, and cancer stage was investigated by examining the scaled
          Schoenfeld residuals. Sex and cancer stage generally displayed a significant deviation
          from this assumption. Therefore, these two variables were taken as strata and others as
          covariates in our Cox proportional hazards model. The plot of global
          <italic>p</italic>-values obtained by testing the proportional hazards assumption for all
          survival-related genes showed that the model used in our survival analysis was
          statistically warranted (<xref ref-type="supplementary-material" rid="pmed-0030467-sg002">Figure S2</xref>). The genes were ranked according to the bootstrap frequencies of
            <italic>p</italic> &lt; 0.01 for their expression in regression models.</p>
        <p>To identify a gene signature predictive of survival outcome, survival analyses were
          performed on all 197 samples in datasets 1 to 5. Partial Cox regression was performed to
          construct predictive components, and time-dependent ROC curve analysis was applied to
          evaluate the results [<xref ref-type="bibr" rid="pmed-0030467-b015">15</xref>]. The risk scores were calculated by a linear combination of the gene
          expression values for the selected genes, weighted by their estimated regression
          coefficients. All the samples were classified into high or low risk groups according to
          the risk scores. To choose an appropriate subset of genes for a common signature, we
          performed a forward selection procedure: (1) increase one gene each time based on the rank
          of genes that were identified in the above bootstrap analyses; (2) perform the partial Cox
          regression analysis and obtain the prediction accuracy using the chosen subset of genes;
          and (3) repeat steps 1 and 2 until the prediction accuracy is maximized. Kaplan-Meier
          survival plots, Mantel-Haenszel log rank tests, and time-dependent ROC analysis were
          implemented to assess the classification models according to the risk scores.</p>
        <p>Hierarchical clustering based on a centered Pearson correlation coefficient algorithm and
          an average linkage method were used to show the expression patterns of survival-related
          genes in datasets 1 to 5.</p>
        <p>All of the data analyses were implemented using the R statistical package [<xref ref-type="bibr" rid="pmed-0030467-b016">16</xref>]. A more detailed description
          of the data analyses is provided (<xref ref-type="supplementary-material" rid="pmed-0030467-sd001">Protocol S1</xref>).</p>
      </sec>
      <sec id="s2d">
        <title>Quantitative RT-PCR Analysis</title>
        <p>Using the samples from dataset 1, the relative expressions of nine randomly selected
          genes associated with survival were determined by quantitative RT-PCR (QRT-PCR) analysis
          as described in a previous report [<xref ref-type="bibr" rid="pmed-0030467-b017">17</xref>]. Primers for the QRT-PCR analysis (<xref ref-type="supplementary-material" rid="pmed-0030467-st002">Table S2</xref>) were
          designed using Primer Express software version 2.0 (Applied Biosystems [<ext-link ext-link-type="uri" xlink:href="http://www.appliedbiosystems.com" xlink:type="simple">http://www.appliedbiosystems.com</ext-link>]). Amplification of each target
          DNA was performed with SYBR Green master mix in Bio-Rad (<ext-link ext-link-type="uri" xlink:href="http://www.bio-rad.com" xlink:type="simple">http://www.bio-rad.com</ext-link>) Single Color
          Real-Time PCR Detection System according to the protocols provided. The control gene
            <italic>β-actin</italic> and the target genes amplified with equal
          efficiencies. To assess whether two amplicons have the same efficiency, the variation of
            ΔC<sub>T</sub> (C<sub>T,target</sub> –
          C<sub>T,β-actin</sub>, where C<sub>T</sub> is cycle number at which the
          fluorescence signal exceeds background) with template dilution was evaluated
            [<xref ref-type="bibr" rid="pmed-0030467-b018">18</xref>]. The fold
          change of gene expression in long-term survival patients relative to short-term survival
          patients was calculated as 2<sup>–ΔΔCT</sup>
            (ΔΔC<sub>T</sub> = ΔC<sub>T long</sub>
          – ΔC<sub>T</sub><sub>short</sub>). ANOVA was performed to determine differences among the groups. A
            <italic>p</italic>-value of less than 0.05 was considered to indicate statistical
          significance.</p>
      </sec>
      <sec id="s2e">
        <title>Tissue Microarray</title>
        <p>Lung tissues of 60 stage I NSCLC patients (including 12 patients dead by 2 years after
          surgical resection and 48 alive for more than 5 years) were collected during surgery
          between 1985 and 1999 at the Arthur James Cancer Hospital of the Ohio State University
          Medical School (Columbus, Ohio, United States). All tissues were fixed in formalin and
          embedded in paraffin. A patient tissue microarray was constructed from these tissues for
          examination of CRABP1 and ABCC1 immunoreactivity in short- and long-term survival
          patients. All antibodies were antigen-retrieved in a vegetable steamer with TRS, pH 6.1
          (Dako [<ext-link ext-link-type="uri" xlink:href="http://www.dako.com" xlink:type="simple">http://www.dako.com</ext-link>]), staining was performed on a Dako
          autostainer, and all primary incubations were for 1 h at room temperature. For CRABP1
          (Abcam [<ext-link ext-link-type="uri" xlink:href="http://www.abcam.com" xlink:type="simple">http://www.abcam.com</ext-link>, #Ab2816], dilution 1:1000), detection
          kit used was LSAB+ (Dako). For ABCC1 (AXXORA [<ext-link ext-link-type="uri" xlink:href="http://www.axxora.com" xlink:type="simple">http://www.axxora.com</ext-link>,
          ALX-801–007-C125], dilution 1:50), the detection kit used was
          Vectastain Elite (Vector Labs [<ext-link ext-link-type="uri" xlink:href="http://www.vectorlabs.com" xlink:type="simple">http://www.vectorlabs.com</ext-link>]).
          The immunohistochemical staining images were scanned using an ImageScope (Aperio
            [<ext-link ext-link-type="uri" xlink:href="http://www.aperio.com" xlink:type="simple">http://www.aperio.com</ext-link>]). The percentage of positive cancer cells
          was scored on a semiquantitative scale as 0 (0%), 1
          (1%–25%), 2 (25%–50%), 3
          (50%–75%), and 4
          (75%–100%). Intensity was scored as 1 (weak), 2
          (intermediate), and 3 (strong). Results were calculated by multiplying the score of
          percentage of positive cells (P) by the intensity (I). The maximum score was 12. Two
          investigators did the evaluation of immunostaining results independently. Student's t-test
          was used in statistical analyses.</p>
      </sec>
    </sec>
    <sec id="s3">
      <title>Results</title>
      <sec id="s3a">
        <title>Differentially Expressed Genes Associated with Survival</title>
        <p><xref ref-type="table" rid="pmed-0030467-t002">Tables 2</xref> and <xref ref-type="supplementary-material" rid="pmed-0030467-sg003">S3</xref> list the genes
          related to overall survival in the combined data (<italic>p</italic> &lt; 0.01). As
          shown in <xref ref-type="table" rid="pmed-0030467-t002">Table 2</xref>, we observed
          relatively consistent changes for both genes whose expression in low-risk patients is
          higher than in high-risk patients and genes whose expression in high-risk patients is
          higher than in low-risk patients. Since we did not use data from normal paired lungs in
          these analyses, it is not clear whether these genes are all overexpressed in both low-risk
          and high-risk patients. Therefore, there are at least four possibilities of
          gene-expression patterns: (1) one group of genes overexpressed in low-risk patients and
          another group of genes overexpressed in high-risk patients; (2) one group of genes
          overexpressed in high-risk patients and another group of genes underexpressed in high-risk
          patients; (3) one group of genes overexpressed in low-risk patients and another group of
          genes underexpressed in low-risk patients; or (4) a mixture of all three scenarios. In
          order to clarify this issue, we have begun to systematically acquire microarray
          information from all paired normal lungs in an attempt to determine possible expression
          patterns of these survival-related genes by comparing normal gene expression levels
          between low-risk and high-risk patients. The results from this ongoing study will be
          included a future publication.</p>
        <table-wrap content-type="2col" id="pmed-0030467-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.0030467.t002</object-id><label>Table 2</label><caption>
            <p>Genes Related to Survival</p>
          </caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.0030467.t002" xlink:type="simple"/><!-- <table frame="hsides" rules="none"><colgroup><col id="tb2col1" align="left" charoff="0" char=""/><col id="tb2col2" align="left" charoff="0" char=""/><col id="tb2col3" align="left" charoff="0" char=""/><col id="tb2col4" align="left" charoff="0" char=""/></colgroup><thead><tr><td align="left"><hr/>Expression</td><td><hr/>Gene</td><td><hr/>Function</td><td><hr/><italic>p</italic>-Value</td></tr></thead><tbody><tr><td><bold>Overexpressed in low-risk patients</bold></td><td><italic>ABI2</italic></td><td>Cell migration</td><td>0.0023</td></tr><tr><td></td><td><italic>APC</italic><sup>a</sup></td><td>Cell adhesion</td><td>0.0037</td></tr><tr><td></td><td><italic>ARHGEF1</italic><sup>a</sup></td><td>Cell proliferation</td><td>0.0031</td></tr><tr><td></td><td><italic>BCL2</italic><sup>a</sup></td><td>Antiapoptosis</td><td>0.0002</td></tr><tr><td></td><td><italic>BNIP1</italic></td><td>Antiapoptosis</td><td>0.0004</td></tr><tr><td></td><td><italic>C21orf33</italic></td><td>Cell wall</td><td>0.0080</td></tr><tr><td></td><td><italic>CASP10</italic><sup>a</sup></td><td>Induction of apoptosis</td><td>0.0082</td></tr><tr><td></td><td><italic>CASP8</italic><sup>a</sup></td><td>Regulation of apoptosis</td><td>0.0070</td></tr><tr><td></td><td><italic>CDH8</italic><sup>a</sup></td><td>Cell adhesion</td><td>0.0007</td></tr><tr><td></td><td><italic>CHRNA2</italic></td><td>Signal transduction</td><td>0.0100</td></tr><tr><td></td><td><italic>DPH2L1</italic></td><td>Cell proliferation</td><td>0.0049</td></tr><tr><td></td><td><italic>DTNA</italic><sup>a</sup></td><td>Signal transduction</td><td>0.0003</td></tr><tr><td></td><td><italic>DYRK1A</italic></td><td>Transferase activity</td><td>0.0019</td></tr><tr><td></td><td><italic>ENPP2</italic><sup>a</sup></td><td>Cell motility, chemotaxis</td><td>0.0036</td></tr><tr><td></td><td><italic>GOLGA1</italic><sup>a</sup></td><td>Golgi autoantigen</td><td>0.0079</td></tr><tr><td></td><td><italic>GPLD1</italic></td><td>Cell matrix adhesion</td><td>0.0037</td></tr><tr><td></td><td><italic>IL8RB</italic><sup>a</sup></td><td>Cell motility, chemotaxis</td><td>0.0090</td></tr><tr><td></td><td><italic>ITGB3</italic></td><td>Cell matrix adhesion</td><td>0.0052</td></tr><tr><td></td><td><italic>ITSN1</italic><sup>a</sup></td><td>Calcium ion binding</td><td>0.0010</td></tr><tr><td></td><td><italic>LST1</italic></td><td>Immune response</td><td>0.0090</td></tr><tr><td></td><td><italic>MAPK14</italic></td><td>MAP kinase activity</td><td>0.0081</td></tr><tr><td></td><td><italic>NIFUN</italic></td><td>Metal ion binding</td><td>0.0066</td></tr><tr><td></td><td><italic>NNT</italic></td><td>Electron transport</td><td>0.0070</td></tr><tr><td></td><td><italic>NTRK3</italic><sup>a</sup></td><td>Cell differentiation</td><td>0.0048</td></tr><tr><td></td><td><italic>PPOX</italic><sup>a</sup></td><td>Electron transport</td><td>0.0030</td></tr><tr><td></td><td><italic>PTGER3</italic></td><td>Cell death</td><td>0.0080</td></tr><tr><td></td><td><italic>RAB28</italic><sup>a</sup></td><td>GTPase activity</td><td>0.0044</td></tr><tr><td></td><td><italic>RAD9A</italic></td><td>Regulation of cell cycle</td><td>0.0075</td></tr><tr><td></td><td><italic>RAE1</italic><sup>a</sup></td><td>Cytoskeleton</td><td>0.0021</td></tr><tr><td></td><td><italic>RBPMS</italic></td><td>RNA processing</td><td>0.0070</td></tr><tr><td></td><td><italic>SELL</italic></td><td>Cell motility</td><td>0.0060</td></tr><tr><td></td><td><italic>SLC15A1</italic></td><td>Oligopeptide transport</td><td>0.0080</td></tr><tr><td></td><td><italic>SLC17A4</italic></td><td>Sodium ion transport</td><td>0.0100</td></tr><tr><td></td><td><italic>SON</italic><sup>a</sup></td><td>Antiapoptosis</td><td>0.0027</td></tr><tr><td></td><td><italic>SUOX</italic></td><td>Metal ion binding</td><td>0.0070</td></tr><tr><td></td><td><italic>TIAL1</italic></td><td>Induction of apoptosis</td><td>0.0060</td></tr><tr><td></td><td><italic>UBE2I</italic></td><td>Ubiquitin cycle</td><td>0.0040</td></tr><tr><td></td><td><italic>CCR2</italic><sup>a</sup></td><td>C-C chemokine receptor activity</td><td>0.0001</td></tr><tr><td></td><td><italic>CDC2L5</italic></td><td>Positive regulation of cell proliferation</td><td>0.0044</td></tr><tr><td></td><td><italic>CUGBP2</italic></td><td>Nuclear mRNA splicing, via spliceosome</td><td>0.0045</td></tr><tr><td></td><td><italic>DBH</italic></td><td>Catecholamine biosynthesis</td><td>0.0031</td></tr><tr><td></td><td><italic>FLT3</italic></td><td>Positive regulation of cell proliferation</td><td>0.0067</td></tr><tr><td></td><td><italic>FUCA1</italic><sup>a</sup></td><td>Carbohydrate metabolism</td><td>0.0026</td></tr><tr><td></td><td><italic>GALGT</italic></td><td>Carbohydrate metabolism</td><td>0.0014</td></tr><tr><td></td><td><italic>GCS1</italic></td><td>Carbohydrate metabolism</td><td>0.0044</td></tr><tr><td></td><td><italic>GGCX</italic></td><td>&gamma;-glutamyl carboxylase activity</td><td>0.0034</td></tr><tr><td></td><td><italic>GLG1</italic></td><td>Fibroblast growth factor binding</td><td>0.0100</td></tr><tr><td></td><td><italic>GM2A</italic></td><td>Sphingolipid catabolism</td><td>0.0100</td></tr><tr><td></td><td><italic>GNAT2</italic><sup>a</sup></td><td>G protein-coupled receptor protein signaling pathway</td><td>0.0027</td></tr><tr><td></td><td><italic>GNRH1</italic></td><td>Negative regulation of cell proliferation</td><td>0.0083</td></tr><tr><td></td><td><italic>GTF2I</italic></td><td>Transcription factor activity</td><td>0.0042</td></tr><tr><td></td><td><italic>INSR</italic></td><td>Epidermal growth factor receptor activity</td><td>0.0070</td></tr><tr><td></td><td><italic>MAP4K1</italic><sup>a</sup></td><td>MAP kinase kinase kinase kinase activity</td><td>0.0060</td></tr><tr><td></td><td><italic>MAPK10</italic></td><td>MAP kinase kinase activity</td><td>0.0090</td></tr><tr><td></td><td><italic>MEF2C</italic><sup>a</sup></td><td>Transcription factor activity</td><td>0.0032</td></tr><tr><td></td><td><italic>MLLT10</italic><sup>a</sup></td><td>Transcription factor activity</td><td>0.0016</td></tr><tr><td></td><td><italic>NFATC3</italic></td><td>Transcription factor activity</td><td>0.0090</td></tr><tr><td></td><td><italic>NR1H4</italic><sup>a</sup></td><td>Transcription factor activity</td><td>0.0000</td></tr><tr><td></td><td><italic>PBP</italic><sup>a</sup></td><td>Serine-type endopeptidase inhibitor activity</td><td>0.0059</td></tr><tr><td></td><td><italic>PIGC</italic><sup>a</sup></td><td>Transferase activity, transfers glycosyl groups</td><td>0.0100</td></tr><tr><td></td><td><italic>PIK3R1</italic><sup>a</sup></td><td>Phosphatidylinositol 3-kinase activity</td><td>0.0050</td></tr><tr><td></td><td><italic>PKNOX1</italic><sup>a</sup></td><td>Transcription factor activity</td><td>0.0031</td></tr><tr><td></td><td><italic>PRKACA</italic><sup>a</sup></td><td>cAMP-dependent protein kinase activity</td><td>0.0001</td></tr><tr><td></td><td><italic>RPS14</italic></td><td>Structural constituent of ribosome</td><td>0.0073</td></tr><tr><td></td><td><italic>SAA4</italic></td><td>Lipid transporter activity</td><td>0.0044</td></tr><tr><td></td><td><italic>SLC35B1</italic></td><td>UDP-galactose transporter activity</td><td>0.0080</td></tr><tr><td></td><td><italic>SNX1</italic><sup>a</sup></td><td>Intracellular protein transport</td><td>0.0055</td></tr><tr><td></td><td><italic>SSR2</italic></td><td>Cotranslational protein-membrane targeting</td><td>0.0046</td></tr><tr><td></td><td><italic>SUPT4H1</italic></td><td>Positive regulation of transcription</td><td>0.0003</td></tr><tr><td></td><td><italic>TMED9</italic></td><td>Intracellular protein transport</td><td>0.0059</td></tr><tr><td></td><td><italic>TMSB4X</italic><sup>a</sup></td><td>Regulation of actin cytoskeleton</td><td>0.0027</td></tr><tr><td></td><td><italic>TRA2A</italic><sup>a</sup></td><td>Nuclear mRNA splicing, via spliceosome</td><td>0.0000</td></tr><tr><td></td><td><italic>ZNFN1A1</italic><sup>a</sup></td><td>Regulation of transcription, DNA-dependent</td><td>0.0002</td></tr><tr><td><bold>Overexpressed in high-risk patients</bold></td><td><italic>ABCA2</italic></td><td>ATPase activity</td><td>0.0024</td></tr><tr><td></td><td><italic>ABCC1</italic><sup>a</sup></td><td>Response to drug</td><td>0.0001</td></tr><tr><td></td><td><italic>ADAM17</italic><sup>a</sup></td><td>Cell-cell signaling</td><td>0.0020</td></tr><tr><td></td><td><italic>BLM</italic><sup>a</sup></td><td>DNA repair</td><td>0.0100</td></tr><tr><td></td><td><italic>C4orf10</italic></td><td></td><td>0.0071</td></tr><tr><td></td><td><italic>CHERP</italic><sup>a</sup></td><td>Neurogenesis</td><td>0.0013</td></tr><tr><td></td><td><italic>CRABP1</italic><sup>a</sup></td><td>Signal transduction</td><td>0.0100</td></tr><tr><td></td><td><italic>HMGB2</italic></td><td>DNA repair</td><td>0.0090</td></tr><tr><td></td><td><italic>INHA</italic><sup>a</sup></td><td>induction of apoptosis</td><td>0.0083</td></tr><tr><td></td><td><italic>LY6D</italic><sup>a</sup></td><td>Cell adhesion</td><td>0.0100</td></tr><tr><td></td><td><italic>NID</italic><sup>a</sup></td><td>Cell matrix adhesion</td><td>0.0009</td></tr><tr><td></td><td><italic>NOTCH3</italic><sup>a</sup></td><td>Cell differentiation</td><td>0.0011</td></tr><tr><td></td><td><italic>PCDHGA12</italic><sup>a</sup></td><td>Cell adhesion</td><td>0.0023</td></tr><tr><td></td><td><italic>PFN2</italic><sup>a</sup></td><td>Actin cytoskeleton</td><td>0.0074</td></tr><tr><td></td><td><italic>PSEN1</italic><sup>a</sup></td><td>Antiapoptosis</td><td>0.0013</td></tr><tr><td></td><td><italic>RIF1</italic></td><td>ATPase activity</td><td>0.0085</td></tr><tr><td></td><td><italic>SEMA3F</italic></td><td>Extracellular space</td><td>0.0100</td></tr><tr><td></td><td><italic>SH3GL2</italic></td><td>Transferase activity</td><td>0.0100</td></tr><tr><td></td><td><italic>SMC1L1</italic><sup>a</sup></td><td>Chromatin binding</td><td>0.0036</td></tr><tr><td></td><td><italic>STC1</italic><sup>a</sup></td><td>Cell division</td><td>0.0090</td></tr><tr><td></td><td><italic>SUMO1</italic></td><td>Ubiquitin cycle</td><td>0.0048</td></tr><tr><td></td><td><italic>TLK1</italic></td><td>Cell cycle</td><td>0.0068</td></tr><tr><td></td><td><italic>TOP3B</italic></td><td>DNA modification</td><td>0.0033</td></tr><tr><td></td><td><italic>UBE3A</italic></td><td>Ubiquitin cycle</td><td>0.0039</td></tr><tr><td></td><td><italic>UGP2</italic></td><td>Kinase activity</td><td>0.0059</td></tr><tr><td></td><td><italic>ZWINTAS</italic><sup>a</sup></td><td>Cell cycle</td><td>0.0019</td></tr><tr><td></td><td><italic>ARL4A</italic><sup>a</sup></td><td>Small GTPase-mediated signal transduction</td><td>0.0012</td></tr><tr><td></td><td><italic>BIK</italic><sup>a</sup></td><td>Induction of apoptosis</td><td>0.0040</td></tr><tr><td></td><td><italic>CBX3</italic></td><td>Regulation of transcription, DNA-dependent</td><td>0.0090</td></tr><tr><td></td><td><italic>DSP</italic><sup>a</sup></td><td>Cell-cell adherens junction</td><td>0.0020</td></tr><tr><td></td><td><italic>ETV6</italic></td><td>Transcription factor activity</td><td>0.0088</td></tr><tr><td></td><td><italic>FBN2</italic><sup>a</sup></td><td>Extracellular matrix structural constituent</td><td>0.0083</td></tr><tr><td></td><td><italic>GABRA3</italic></td><td>&gamma;-aminobutyric acid signaling pathway</td><td>0.0045</td></tr><tr><td></td><td><italic>GLI2</italic><sup>a</sup></td><td>Transcription factor activity</td><td>0.0085</td></tr><tr><td></td><td><italic>HNRPD</italic><sup>a</sup></td><td>Regulation of transcription, DNA-dependent</td><td>0.0031</td></tr><tr><td></td><td><italic>IRS1</italic><sup>a</sup></td><td>Insulin receptor binding</td><td>0.0072</td></tr><tr><td></td><td><italic>LARS2</italic><sup>a</sup></td><td>Leucine-tRNA ligase activity</td><td>0.0020</td></tr><tr><td></td><td><italic>LHCGR</italic></td><td>Lutropin-choriogonadotropic hormone receptor activity</td><td>0.0039</td></tr><tr><td></td><td><italic>OLFM1</italic></td><td>Latrotoxin receptor activity</td><td>0.0100</td></tr><tr><td></td><td><italic>PLEC1</italic><sup>a</sup></td><td>Structural constituent of cytoskeleton</td><td>0.0030</td></tr><tr><td></td><td><italic>PPP2R4</italic></td><td>Phosphatase activator activity</td><td>0.0026</td></tr><tr><td></td><td><italic>PYGL</italic><sup>a</sup></td><td>Glycogen metabolism</td><td>0.0025</td></tr><tr><td></td><td><italic>SLC2A1</italic><sup>a</sup></td><td>Carbohydrate transport</td><td>0.0024</td></tr><tr><td></td><td><italic>SLC7A1</italic><sup>a</sup></td><td>Basic amino acid transporter activity</td><td>0.0016</td></tr><tr><td></td><td><italic>SMARCA3</italic><sup>a</sup></td><td>Chromatin modification</td><td>0.0066</td></tr><tr><td></td><td><italic>TFAM</italic></td><td>DNA-dependent DNA replication</td><td>0.0014</td></tr><tr><td></td><td><italic>UPK2</italic><sup>a</sup></td><td>Membrane organization and biogenesis</td><td>0.0055</td></tr><tr><td></td><td><italic>VARS2</italic></td><td>Translational elongation</td><td>0.0072</td></tr><tr><td></td><td><italic>VGLL1</italic><sup>a</sup></td><td>Transcription regulator activity</td><td>0.0032</td></tr><tr><td></td><td><italic>ZNF154</italic><sup>a</sup></td><td>Regulation of transcription, DNA-dependent</td><td>0.0044</td></tr><tr><td></td><td><italic>ZNF410</italic><sup>a</sup></td><td>Regulation of transcription, DNA-dependent</td><td>0.0004</td></tr></tbody></table> --><!-- <table-wrap-foot><fn id="nt201"><p><sup>a</sup>Included in group of 64 genes chosen for calculating risk scores of overall survival.</p></fn></table-wrap-foot> --></table-wrap>
        <p>Most of these genes are related to cell adhesion, cell motility, cell proliferation, and
          apoptosis. Notably, several genes have been reported to be associated with cancer survival
            <italic>(APC, IRS1, SLC2A1, BCL2, ABCC1, FLT3, RAD9A, Inhibin A, NTRK3, CASP8,</italic>
          and <italic>CASP10).</italic> The <italic>APC</italic> gene plays a role in NSCLC, and
          high <italic>APC</italic> promoter methylation is significantly associated with poor
          survival in NSCLC [<xref ref-type="bibr" rid="pmed-0030467-b019">19</xref>]. <italic>IRS1</italic> is a high-risk classifier gene associated with
          cancer death within 12 months [<xref ref-type="bibr" rid="pmed-0030467-b008">8</xref>]. In another study, <italic>BCL2</italic> was observed to be
          up-regulated in a group of long-term survival patients with NSCLC [<xref ref-type="bibr" rid="pmed-0030467-b020">20</xref>]. <italic>ABCC1</italic>
          expression levels have been shown to be an independent predictor for disease-free survival
          in adult acute myeloid leukemia [<xref ref-type="bibr" rid="pmed-0030467-b021">21</xref>]. Acute myeloid leukemia patients with <italic>FLT3</italic> mutations
          tend to have poor prognoses [<xref ref-type="bibr" rid="pmed-0030467-b022">22</xref>]. In addition, <italic>RAD9A</italic>, which is involved in DNA
          repair, was found to be increased in radioresistant cells over radiosensitive cells
            [<xref ref-type="bibr" rid="pmed-0030467-b023">23</xref>].
            <italic>Inhibin A</italic> was found to be overexpressed in two cases of primary clear
          cell renal cell carcinoma (2/16 [13%]) and three cases of
          metastatic clear cell renal cell carcinoma (3/5 [60%])
            [<xref ref-type="bibr" rid="pmed-0030467-b024">24</xref>]. The
          expression of CASP8 and CASP10 was frequently decreased at the mRNA and protein levels in
          lung cancer progression [<xref ref-type="bibr" rid="pmed-0030467-b025">25</xref>]. We found that the genes encoding these two caspases were
          up-regulated in long-term survival patients. High <italic>NTRK3</italic> mRNA expression
          generally presages longer survival [<xref ref-type="bibr" rid="pmed-0030467-b026">26</xref>]. Four survival genes <italic>(TMSB4X, INHA, FUCA1,</italic> and
            <italic>STC1)</italic> were previously identified by the cross-validation procedure in
          dataset 3 [<xref ref-type="bibr" rid="pmed-0030467-b005">5</xref>]. Not
          surprisingly, several genes were reported to be involved in cancer progression, survival,
          or cancer subtypes in the original reports. For example, <italic>ATP2B1, AKAP12, TNFAIP6,
            RGS16, HSPA8, RPS3, ADM,</italic> and <italic>P2RX5</italic> are survival-associated
          genes [<xref ref-type="bibr" rid="pmed-0030467-b008">8</xref>].
            <italic>MUC1</italic> may play a role in progression and invasiveness of colorectal
          carcinomas [<xref ref-type="bibr" rid="pmed-0030467-b027">27</xref>].
          Finally <italic>AGT, XBP1,</italic> and <italic>PODXL</italic> are overexpressed in ADC
          compared with SCC [<xref ref-type="bibr" rid="pmed-0030467-b028">28</xref>].</p>
      </sec>
      <sec id="s3b">
        <title>Validation of Selected Genes</title>
        <p>To validate the microarray gene expression results from the meta-analysis, the relative
          expression of nine genes associated with overall survival <italic>(CRABP1, BLM, ABCC1,
            SLC2A1, TNFSF4, BCL2, LST1, STC1,</italic> and <italic>LARS2)</italic> was determined by
          QRT-PCR analysis on the samples from dataset 1. We confirmed the expression results for
          all these nine genes except <italic>BCL2</italic> (<italic>p</italic> ≤ 0.05)
            (<xref ref-type="fig" rid="pmed-0030467-g001">Figure 1</xref>A).</p>
        <fig id="pmed-0030467-g001" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pmed.0030467.g001</object-id>
          <label>Figure 1</label>
          <caption>
            <title>Validation Analyses of Gene Expression Profiling</title>
            <p>(A) QRT-PCR validations of several candidate survival-related genes. Bars represent
              fold changes for the selected genes with differential expression between long-
              (&gt;5 y) and short-term survival (&lt;2 y) patients. Positive fold change
              represents up-regulated, and negative fold change represents down-regulated in
              short-term survival patients. * <italic>p</italic> ≤ 0.05; **
              <italic>p</italic> ≤ 0.01; *** <italic>p</italic> ≤ 0.005.</p>
            <p>(B and C) Immunostaining analysis of CRABP1 and ABCC1 expression in long- and short-
              term survival lung cancer patients. Low magnification (B) and 40× (C).
              Positive CRABP1 immunoreactivity was observed in cytoplasm of an acinar ADC (lower
              left photomicrographs of B and C) from short-term survival patients, and no CRABP1
              reactivity was seen in a lung ADC from a long-term survival patient (upper left).
              Strong ABCC1 membranous staining (lower right) in tumor cells from short-term survival
              patients was observed, and weak ABCC1 reactivity was seen in a lung ADC from a
              long-term survival patient (upper right).</p>
            <p>(D) Distribution of CRABP1 and ABCC1 protein levels in short- and long-term survival
              patients.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.0030467.g001" xlink:type="simple"/>
        </fig>
        <p>The patient tissue microarray of 60 completely independent patients was interrogated for
            <italic>CRABP1</italic> and <italic>ABCC1</italic> to determine if mRNA changes were
          correlated with increased protein expression in lung ADCs from patients with short-term
          survival. CRABP1 staining was observed in the cytoplasm of tumor cells in most lung tumor
          tissues (<xref ref-type="fig" rid="pmed-0030467-g001">Figure 1</xref>B and <xref ref-type="fig" rid="pmed-0030467-g001">1</xref>C). CRABP1 exhibited stronger staining in
          tissues of short-term survival patients than in those of long-term survival patients
            (<xref ref-type="fig" rid="pmed-0030467-g001">Figures 1</xref>B, <xref ref-type="fig" rid="pmed-0030467-g001">1</xref>C, and <xref ref-type="supplementary-material" rid="pmed-0030467-sg003">S3</xref>), the scores for short- and long-term survival were
          8.8 ± 3.1(mean ± SD, same hereafter) and 4.9 ± 2.8
            (<italic>p</italic> &lt; 0.0001), respectively. In short-term survival patients,
          80% and 20% of the samples had scores of 8 or higher and 4 or lower
          in CRABP1 immunostaining, respectively; in contrast, in long-term survival patients,
          34% and 59% of the samples had scores of 8 or higher and 4 or lower,
          respectively (<xref ref-type="fig" rid="pmed-0030467-g001">Figure 1</xref>D). Similar
          trends were also observed in mRNA levels in our samples (see <xref ref-type="fig" rid="pmed-0030467-g001">Figure 1</xref>A). ABCC1 showed either membranous or cytoplasmic
          staining in tumor cells of tissues of both short- and long-term survival NSCLC patients
            (<xref ref-type="fig" rid="pmed-0030467-g001">Figures 1</xref>B, <xref ref-type="fig" rid="pmed-0030467-g001">1</xref>C, and <xref ref-type="supplementary-material" rid="pmed-0030467-sg003">S3</xref>). A significant increase in scores of ABCC1-positive
          staining was also present in tissues of short-term survival patients; the scores in
          tissues of short-term and long-term survival patients were 10 ± 2.3 and 6.6
          ± 3.1 (<italic>p =</italic> 0.002), respectively. In short-term
          survival patients, 91% and 9% of the samples had ABCC1
          immunostaining scores of 8 or higher and 4 or lower, respectively; in long-term survival
          patients, 45% and 48% of the samples had scores 8 or higher and 4 or
          lower, respectively. The results indicate that expression of these two proteins is
          consistent with the results from both microarray and RT-PCR analyses. Higher protein
          levels of CRABP1 and ABCC1 tend to increase risk of short survival of stage I NSCLC
          patients.</p>
      </sec>
      <sec id="s3c">
        <title>Identification of a Gene Expression Signature for Survival</title>
        <p>Next, we determined if a subset of the genes related to overall survival can be used to
          predict survival of patients with stage I NSCLC. Risk scores were derived from survival
          analyses of all 197 samples in datasets 1 to 5 with the partial Cox regression.
          Kaplan-Meier survival analyses were performed after the samples were classified into high-
          and low-risk groups according to the risk scores. As shown in <xref ref-type="fig" rid="pmed-0030467-g002">Figure 2</xref>A, Kaplan-Meier survival curves indicated poorer
          survival in stage IB than in stage IA NSCLC (<italic>p</italic> = 0.032). To
          determine whether gene expression profiles could accurately predict overall survival, the
          risk scores calculated by the 64 genes (listed in <xref ref-type="table" rid="pmed-0030467-t002">Table 2</xref>) were used to classify all of the samples from
          datasets 1 to 5 into two groups as high and low risk groups. Kaplan-Meier analysis using
          expression profiles demonstrated that the high and low-risk groups were significantly
          different in their overall survival (<italic>p</italic> &lt; 0.001) (<xref ref-type="fig" rid="pmed-0030467-g002">Figure 2</xref>B). A comparison of <xref ref-type="fig" rid="pmed-0030467-g002">Figure 2</xref>A and <xref ref-type="fig" rid="pmed-0030467-g002">2</xref>B clearly shows that the gene expression signature has
          higher classification power than the staging method. The former has a larger area between
          the two risk groups and a smaller <italic>p</italic>-value from the Mantel-Haenszel log
          rank test. <xref ref-type="fig" rid="pmed-0030467-g002">Figure 2</xref>C shows the
          time-dependent area under the ROC curves based on the stage information or the estimated
          risk scores of the patients. We observed that the Cox model with gene expression data gave
          the better predictive performance with the areas under the ROC curve close to
          80%. The Cox model with stage information, in contrast, resulted in areas under
          the curve below 60%.</p>
        <fig id="pmed-0030467-g002" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pmed.0030467.g002</object-id>
          <label>Figure 2</label>
          <caption>
            <title>Survival Analyses of Stage I NSCLC</title>
            <p>(A) Kaplan-Meier survival curves for patients with stage IA and with IB NSCLC.</p>
            <p>(B) Kaplan-Meier survival curves for stage IA and IB patients defined by having
              positive (high-risk) or negative (low-risk) risk scores of overall survival. The risk
              scores were estimated with seven principle components based on the model built by 64
              survival-related genes identified in five datasets.</p>
            <p>(C) Area under the ROC curve for survival models based on stage information or
              expression data, respectively.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.0030467.g002" xlink:type="simple"/>
        </fig>
        <p>Patients with a postoperative survival of at least 5 years and those who died within 2
          years after resection were selected for estimating the predictive power of Kaplan-Meier
          survival analysis using expression profiles. According to the risk scores by the partial
          Cox regression approach, 77 of the 88 patients were classified correctly (87%
          accuracy) (<xref ref-type="supplementary-material" rid="pmed-0030467-st004">Table
          S4</xref>). Gene expression patterns were determined using hierarchical clustering of the
          197 NSCLC samples against the 64 top survival-related genes (<xref ref-type="fig" rid="pmed-0030467-g003">Figure 3</xref>). Short- and long-term survival NSCLC patients
          had distinct expression patterns among the 64 genes that were used for establishing a gene
          expression signature predictive of stage I NSCLC survival.</p>
        <fig id="pmed-0030467-g003" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pmed.0030467.g003</object-id>
          <label>Figure 3</label>
          <caption>
            <title>Gene Expression Patterns of 64 Top Survival Genes for 197 NSCLC Patients from
              Datasets 1 to 5</title>
            <p>Patients were generally classified into two groups (short-term versus long-term
              survival) with distinct expression patterns. The first column on the left represents
              patient status: 0, alive; 1, dead; the second column on the left represents follow-up
              time (days).</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.0030467.g003" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s3d">
        <title>Confirmation of the Gene Expression Signature in Independent Datasets</title>
        <p>The robustness of the 64-gene expression signature in predicting survival in lung cancer
          was further tested with oligonucleotide gene expression data obtained from two completely
          independent datasets—dataset 6 (63 stage I lung ADC including nine long-term
          survival patients and five short-term survivors) and dataset 7 (64 stage I lung ADC and
          SCC, including eight long-term survival patients and twelve short-term survivors). When we
          examined the risk assignment of the samples in these two datasets using the risk scores
          based on our 64-gene signature, high- and low-risk groups were observed that differed
          significantly in survival in datasets 6 and 7. One of 14 individuals was classified
          incorrectly (93% accuracy) using the 64-gene signature in dataset 6
          (<italic>p</italic> &lt; 0.001; <xref ref-type="fig" rid="pmed-0030467-g004">Figure
          4</xref>A). In dataset 7, we correctly classified all 20 patients who survived for at
          least 5 years or died within 2 years using the 64-gene signature (<italic>p</italic>
          &lt; 0.001; <xref ref-type="fig" rid="pmed-0030467-g004">Figure 4</xref>C). We also
          examined the risk assignment of the samples in these two datasets using the risk scores
          based on the 50-gene signature reported by Beer et al. [<xref ref-type="bibr" rid="pmed-0030467-b005">5</xref>]. Classification was less accurate with this
          gene signature: three patients who lived for more than 5 years in dataset 6 were
          classified into the low-risk group according the risk scores calculated by our gene
          signature, but all of these patients were classified into the high-risk group under the
          Beer et al. [<xref ref-type="bibr" rid="pmed-0030467-b005">5</xref>]
          gene signature (<xref ref-type="fig" rid="pmed-0030467-g004">Figure 4</xref>A and <xref ref-type="fig" rid="pmed-0030467-g004">4</xref>B). Also, in dataset 7 one patient
          surviving for more than 2,476 days was classified into the high-risk group under the Beer
          et al. [<xref ref-type="bibr" rid="pmed-0030467-b005">5</xref>] gene
          signature (<xref ref-type="fig" rid="pmed-0030467-g004">Figure 4</xref>D).</p>
        <fig id="pmed-0030467-g004" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pmed.0030467.g004</object-id>
          <label>Figure 4</label>
          <caption>
            <title>Comparison of the Prediction Accuracy of Lung Cancer Survival Using Our 64-Gene
              Signature and a Different 50-Gene Signature</title>
            <p>(A and B) Kaplan-Meier survival curves for dataset 6 under our 64-gene signature (A)
              and the 50-gene signature from Beer et al. [<xref ref-type="bibr" rid="pmed-0030467-b005">5</xref>] (B). Scores were estimated using two
              principle components.</p>
            <p>(C and D) Kaplan-Meier survival curves for dataset 7 using our 64-gene signature (C)
              and the 50-gene signature from Beer et al. [<xref ref-type="bibr" rid="pmed-0030467-b005">5</xref>] (D). Scores were estimated using eight
              principle components.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.0030467.g004" xlink:type="simple"/>
        </fig>
      </sec>
    </sec>
    <sec id="s4">
      <title>Discussion</title>
      <p>In this study, we combined several lung cancer gene expression studies based on Affymetrix
        microarray platforms into a single, homogeneous dataset by using the DWD method. The
        increased sample size was intended to reduce false positives and increase statistical power
        in detecting survival-related genes. This improved dataset enabled us to identify a gene
        expression signature consisting of 64 genes that can accurately predict which stage I lung
        cancer patients may experience poor survival following resection.</p>
      <p>In general, the pathologic diagnosis used to classify a lung tumor is combined with the
        stage of the cancer to predict patient survival and direct therapy [<xref ref-type="bibr" rid="pmed-0030467-b029">29</xref>]. Unfortunately, current
        methods of classification and staging are not completely reliable or sufficiently precise
          [<xref ref-type="bibr" rid="pmed-0030467-b002">2</xref>], and no
        reliable markers exist to predict the presence of micrometastasis or outcome in patients
        with resected NSCLC. It is not unusual for patients with lung cancers of identical
        histology, differentiation, location, and stage to have major differences in survival or
        response to therapy [<xref ref-type="bibr" rid="pmed-0030467-b029">29</xref>]. Some patients diagnosed with stage I NSCLC survive after surgery for
        some time, whereas others do not. This prognostic variability makes the results of this
        study important. Patients whose early-stage tumors contain signatures predicting short
        survival times would benefit from the aggressive therapies currently given only to those
        with later-stage cancers.</p>
      <p>In this study, we included cancer subtypes as a factor in the ANOVA model to choose
        survival-related genes, and we adjusted cancer subtypes in the multivariate Cox proportional
        hazards regression analyses. Therefore, the gene expression signatures identified in the
        current study should be suitable for both lung ADC and SCC. This generalization of our gene
        signatures was also demonstrated in two independent large datasets—dataset 6 (63
        stage I lung ADC including nine long-term and five short-term survival patients) and dataset
        7 (64 stage I lung ADC and SCC, including eight long-term and 12 short-term survival
        patients). Our gene signatures can accurately predict patient survivals in these two
        datasets with mixed stage I lung cancer subtypes. To our knowledge, such signatures have not
        been convincingly reported previously, and we propose that they should be used to inform the
        clinical management of lung cancer patients.</p>
      <p>Our survival gene signatures consist of genes that are involved in cancer metastasis such
        as cell adhesion <italic>(APC, CDH8, DSP, LY6D, PCDHGA12,</italic> and
        <italic>NID),</italic> cell motility <italic>(IL8RB, ENPP2,</italic> and
        <italic>CCR2),</italic> and inflammation and immune response <italic>(CASP8</italic> and
          <italic>CASP10)</italic>. In addition, seven of the genes are related to apoptosis
          <italic>(INHA, PSEN1, CASP8, CASP10, PIK3R1, BCL2,</italic> and <italic>BIK)</italic> and
        another five are related to transport mechanisms <italic>(ABCC1, ITSN1, CRABP1,
        SLC2A1,</italic> and <italic>ZWINTAS)</italic>. Nine of the signature genes were previously
        identified as lung cancer survival factors (<xref ref-type="table" rid="pmed-0030467-t003">Table 3</xref>), and 29 genes have been associated with survival in other cancer types
        including breast carcinoma, brain cancer, and gastric cancer (<xref ref-type="table" rid="pmed-0030467-t004">Table 4</xref>).</p>
      <table-wrap content-type="1col" id="pmed-0030467-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.0030467.t003</object-id><label>Table 3</label><caption>
          <p>The Signature Genes of Survival Identified in Our Meta-Analysis Overlap Those in
            Previous Studies of Lung Cancer Survival</p>
        </caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.0030467.t003" xlink:type="simple"/><!-- <table frame="hsides" rules="none"><colgroup><col id="tb3col1" align="left" charoff="0" char=""/><col id="tb3col2" align="left" charoff="0" char=""/><col id="tb3col3" align="left" charoff="0" char=""/></colgroup><thead><tr><td align="left"><hr/>Gene</td><td><hr/>Methods of Analysis</td><td><hr/>References</td></tr></thead><tbody><tr><td><italic>APC</italic></td><td>Hypermethylation, quantitative fluorogenic RT-PCR</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b019">19</xref>&rsqb;</td></tr><tr><td><italic>BCL2</italic></td><td>Hemotoxylin-eosin staining</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b039">39</xref>&rsqb;</td></tr><tr><td></td><td>Meta-analysis</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b040">40</xref>&rsqb;</td></tr><tr><td><italic>FBN2</italic></td><td>RT-PCR and methylation-specific PCR</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b041">41</xref>&rsqb;</td></tr><tr><td><italic>TMSB4X</italic></td><td>Microarray</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b005">5</xref>&rsqb;</td></tr><tr><td><italic>FUCA1</italic></td><td>Microarray</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b005">5</xref>&rsqb;</td></tr><tr><td><italic>STC1</italic></td><td>Microarray</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b005">5</xref>&rsqb;</td></tr><tr><td><italic>SLC2A1</italic></td><td>Immunohistochemical analysis</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b033">33</xref>&rsqb;</td></tr><tr><td></td><td>Immunohistochemical analysis</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b042">42</xref>&rsqb;</td></tr><tr><td></td><td>Microarray</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b005">5</xref>&rsqb;</td></tr><tr><td><italic>INHA</italic></td><td>Microarray</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b005">5</xref>&rsqb;</td></tr><tr><td><italic>ABCC1</italic></td><td>Review</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b043">43</xref>&rsqb;</td></tr></tbody></table> --><!-- --></table-wrap>
      <table-wrap content-type="2col" id="pmed-0030467-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.0030467.t004</object-id><label>Table 4</label><caption>
          <p>The Signature Genes of Survival Identified in Our Meta-Analysis Are Also Involved in
            Survival of Other Cancer Types</p>
        </caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.0030467.t004" xlink:type="simple"/><!-- <table frame="hsides" rules="none"><colgroup><col id="tb4col1" align="left" charoff="0" char=""/><col id="tb4col2" align="left" charoff="0" char=""/><col id="tb4col3" align="left" charoff="0" char=""/><col id="tb4col4" align="left" charoff="0" char=""/><col id="tb4col5" align="left" charoff="0" char=""/><col id="tb4col6" align="left" charoff="0" char=""/><col id="tb4col7" align="char" charoff="0" char="."/><col id="tb4col8" align="char" charoff="0" char="."/><col id="tb4col9" align="left" charoff="0" char=""/></colgroup><thead><tr><td align="left"><hr/>Gene</td><td><hr/>Cancer Type</td><td><hr/>Measure</td><td><hr/>Survival Time (y)</td><td><hr/>Class 1 (<italic>n</italic>)</td><td><hr/>Class 2 (<italic>n</italic>)</td><td><hr/>t-Test</td><td><hr/><italic>p</italic>-Value<sup>a</sup></td><td><hr/>Reference</td></tr></thead><tbody><tr><td><italic>CRABP1</italic></td><td>Brain</td><td>Survival</td><td>3</td><td>Alive (13)</td><td>Dead (56)</td><td>&minus;2.907</td><td>0.005</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b044">44</xref>&rsqb;</td></tr><tr><td></td><td>Brain</td><td>Survival</td><td>3</td><td>Alive (9)</td><td>Dead (20)</td><td>&minus;2.107</td><td>0.045</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b045">45</xref>&rsqb;</td></tr><tr><td><italic>BLM</italic></td><td>Breast carcinoma</td><td>Disease-free survival</td><td>5</td><td>No disease (196)</td><td>Relapse (79)</td><td>&minus;4.363</td><td>&lt;0.001</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b046">46</xref>&rsqb;</td></tr><tr><td><italic>ABCC1</italic></td><td>Gastric cancer</td><td>Survival</td><td>3</td><td>Alive (23)</td><td>Dead (40)</td><td>&minus;3.033</td><td>0.005</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b047">47</xref>&rsqb;</td></tr><tr><td></td><td>Brain</td><td>Survival</td><td>3</td><td>Alive (13)</td><td>Dead (56)</td><td>&minus;2.806</td><td>0.009</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b044">44</xref>&rsqb;</td></tr><tr><td></td><td>Breast carcinoma</td><td>Disease-free survival</td><td>5</td><td>No disease (180)</td><td>Relapse (93)</td><td>&minus;2.857</td><td>0.005</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b048">48</xref>&rsqb;</td></tr><tr><td><italic>SLC2A1</italic></td><td>Breast carcinoma</td><td>Disease-free survival</td><td>5</td><td>No disease (196)</td><td>Relapse (79)</td><td>&minus;3.409</td><td>&lt;0.001</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b046">46</xref>&rsqb;</td></tr><tr><td><italic>BCL2</italic></td><td>Breast carcinoma</td><td>Disease-free survival</td><td>5</td><td>No disease (196)</td><td>Relapse (79)</td><td>4.243</td><td>&lt;0.001</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b046">46</xref>&rsqb;</td></tr><tr><td></td><td>Breast carcinoma</td><td>Relapse-free survival</td><td>5</td><td>No disease (11)</td><td>Relapse (35)</td><td>3.022</td><td>0.007</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b049">49</xref>&rsqb;</td></tr><tr><td><italic>LST1</italic></td><td>Breast carcinoma</td><td>Disease-free survival</td><td>5</td><td>No disease (180)</td><td>Relapse (93)</td><td>3.568</td><td>&lt;0.001</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b048">48</xref>&rsqb;</td></tr><tr><td></td><td>Breast carcinoma</td><td>Metastases</td><td>5</td><td>Negative (51)</td><td>positive (46)</td><td>2.806</td><td>0.006</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b050">50</xref>&rsqb;</td></tr><tr><td><italic>STC1</italic></td><td>Brain</td><td>Survival</td><td>3</td><td>Alive (9)</td><td>Dead (20)</td><td>&minus;3.762</td><td>&lt;0.001</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b045">45</xref>&rsqb;</td></tr><tr><td></td><td>Brain</td><td>Survival</td><td>3</td><td>Alive (13)</td><td>Dead (56)</td><td>&minus;3.634</td><td>&lt;0.001</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b044">44</xref>&rsqb;</td></tr><tr><td><italic>CDH8</italic></td><td>Brain</td><td>Survival</td><td>3</td><td>Alive (13)</td><td>Dead (56)</td><td>4.139</td><td>&lt;0.001</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b044">44</xref>&rsqb;</td></tr><tr><td><italic>ENPP2</italic></td><td>Breast carcinoma</td><td>Disease-free survival</td><td>5</td><td>No Disease (180)</td><td>Relapse (93)</td><td>2.742</td><td>0.007</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b048">48</xref>&rsqb;</td></tr><tr><td><italic>ITSN1</italic></td><td>Brain</td><td>Survival</td><td>3</td><td>Alive (13)</td><td>Dead (56)</td><td>2.351</td><td>0.033</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b044">44</xref>&rsqb;</td></tr><tr><td></td><td>Breast carcinoma</td><td>Disease-free survival</td><td>5</td><td>No Disease (180)</td><td>Relapse (93)</td><td>2.753</td><td>0.007</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b048">48</xref>&rsqb;</td></tr><tr><td><italic>PBP</italic></td><td>Brain</td><td>Survival</td><td>3</td><td>Alive (13)</td><td>Dead (56)</td><td>3.328</td><td>0.003</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b044">44</xref>&rsqb;</td></tr><tr><td></td><td>Medulloblastoma</td><td>Survival</td><td>5</td><td>Alive (21)</td><td>Dead (18)</td><td>3.505</td><td>0.001</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b051">51</xref>&rsqb;</td></tr><tr><td></td><td>Breast carcinoma</td><td>Disease-free survival</td><td>5</td><td>No disease (180)</td><td>Relapse (93)</td><td>3.019</td><td>0.003</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b048">48</xref>&rsqb;</td></tr><tr><td></td><td>Breast carcinoma</td><td>Metastases</td><td>5</td><td>Negative (51)</td><td>Positive (46)</td><td>2.273</td><td>0.025</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b050">50</xref>&rsqb;</td></tr><tr><td></td><td>Breast Ductal Carcinoma</td><td>Survival</td><td>5</td><td>Alive (70)</td><td>Dead (28)</td><td>2.072</td><td>0.043</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b052">52</xref>&rsqb;</td></tr><tr><td><italic>PIK3R1</italic></td><td>Brain</td><td>Survival</td><td>3</td><td>Alive (13)</td><td>Dead (56)</td><td>3.42</td><td>0.002</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b044">44</xref>&rsqb;</td></tr><tr><td></td><td>Brain</td><td>Survival</td><td>3</td><td>Alive (9)</td><td>Dead (20)</td><td>2.249</td><td>0.033</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b045">45</xref>&rsqb;</td></tr><tr><td></td><td>Breast carcinoma</td><td>Disease-free survival</td><td>5</td><td>No disease (196)</td><td>Relapse (79)</td><td>2.871</td><td>0.005</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b046">46</xref>&rsqb;</td></tr><tr><td></td><td>Breast carcinoma</td><td>Disease-free survival</td><td>5</td><td>No disease (180)</td><td>Relapse (93)</td><td>2.711</td><td>0.007</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b048">48</xref>&rsqb;</td></tr><tr><td><italic>DSP</italic></td><td>Breast carcinoma</td><td>Metastases</td><td>5</td><td>Negative (51)</td><td>Positive (46)</td><td>&minus;3.338</td><td>0.001</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b050">50</xref>&rsqb;</td></tr><tr><td></td><td>Breast ductal carcinoma</td><td>Survival</td><td>5</td><td>Alive (70)</td><td>Dead (28)</td><td>&minus;2.038</td><td>0.045</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b052">52</xref>&rsqb;</td></tr><tr><td><italic>CHERP</italic></td><td>Brain</td><td>Survival</td><td>3</td><td>Alive (9)</td><td>Dead (20)</td><td>&minus;3.075</td><td>0.007</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b045">45</xref>&rsqb;</td></tr><tr><td></td><td>Brain</td><td>Survival</td><td>3</td><td>Alive (13)</td><td>Dead (56)</td><td>&minus;2.429</td><td>0.029</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b044">44</xref>&rsqb;</td></tr><tr><td><italic>SLC7A1</italic></td><td>Breast carcinoma</td><td>Disease-free survival</td><td>5</td><td>No disease (196)</td><td>Relapse (79)</td><td>&minus;3.476</td><td>&lt;0.001</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b046">46</xref>&rsqb;</td></tr><tr><td></td><td>Breast carcinoma</td><td>Disease-free survival</td><td>5</td><td>No disease (180)</td><td>Relapse (93)</td><td>&minus;2.72</td><td>0.007</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b048">48</xref>&rsqb;</td></tr><tr><td></td><td>Breast carcinoma</td><td>Metastases</td><td>5</td><td>Negative (51)</td><td>Positive (46)</td><td>&minus;3.263</td><td>0.002</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b050">50</xref>&rsqb;</td></tr><tr><td><italic>HNRPD</italic></td><td>Brain</td><td>Survival</td><td>3</td><td>Alive (13)</td><td>Dead (56)</td><td>&minus;2.158</td><td>0.038</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b044">44</xref>&rsqb;</td></tr><tr><td><italic>IRS1</italic></td><td>Clear cell renal cell carcinoma</td><td>Survival</td><td>3</td><td>Alive (7)</td><td>Dead (33)</td><td>&minus;3.316</td><td>0.004</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b053">53</xref>&rsqb;</td></tr><tr><td></td><td>Brain</td><td>Survival</td><td>3</td><td>Alive (13)</td><td>Dead (56)</td><td>&minus;4.539</td><td>&lt;0.001</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b044">44</xref>&rsqb;</td></tr><tr><td><italic>CASP10</italic></td><td>Brain</td><td>Survival</td><td>3</td><td>Alive (13)</td><td>Dead (56)</td><td>3.269</td><td>0.004</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b044">44</xref>&rsqb;</td></tr><tr><td><italic>ARHGEF1</italic></td><td>Breast carcinoma</td><td>Disease-free survival</td><td>5</td><td>No disease (180)</td><td>Relapse (93)</td><td>2.634</td><td>0.009</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b048">48</xref>&rsqb;</td></tr><tr><td><italic>PRKACA</italic></td><td>Diffuse large B cell lymphoma</td><td>Survival</td><td>5</td><td>Alive (86)</td><td>Dead (121)</td><td>3.387</td><td>&lt;0.001</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b054">54</xref>&rsqb;</td></tr><tr><td><italic>PYGL</italic></td><td>Brain</td><td>Survival</td><td>3</td><td>Alive (13)</td><td>Dead (56)</td><td>&minus;4.539</td><td>&lt;0.001</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b044">44</xref>&rsqb;</td></tr><tr><td><italic>GLI2</italic></td><td>Gastric cancer</td><td>Survival</td><td>3</td><td>Alive (23)</td><td>Dead (40)</td><td>&minus;2.731</td><td>0.009</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b047">47</xref>&rsqb;</td></tr><tr><td><italic>ZWINTAS</italic></td><td>Breast carcinoma</td><td>Disease-free survival</td><td>5</td><td>No disease (196)</td><td>Relapse (79)</td><td>&minus;5.985</td><td>&lt;0.001</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b046">46</xref>&rsqb;</td></tr><tr><td></td><td>Breast carcinoma</td><td>Disease-free survival</td><td>5</td><td>No disease (180)</td><td>Relapse (93)</td><td>&minus;2.825</td><td>0.005</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b048">48</xref>&rsqb;</td></tr><tr><td></td><td>Breast carcinoma</td><td>Metastases</td><td>5</td><td>Negative (51)</td><td>positive (46)</td><td>&minus;3.248</td><td>0.002</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b050">50</xref>&rsqb;</td></tr><tr><td>PLEC1</td><td>Clear cell renal cell carcinoma</td><td>Survival</td><td>3</td><td>Alive (7)</td><td>Dead (33)</td><td>&minus;3.316</td><td>0.004</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b053">53</xref>&rsqb;</td></tr><tr><td>VGLL1</td><td>Breast carcinoma</td><td>Disease-free survival</td><td>5</td><td>No disease (196)</td><td>Relapse (79)</td><td>&minus;3.202</td><td>0.002</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b046">46</xref>&rsqb;</td></tr><tr><td></td><td>Breast carcinoma</td><td>Metastases</td><td>5</td><td>Negative (51)</td><td>positive (46)</td><td>&minus;2.327</td><td>0.023</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b050">50</xref>&rsqb;</td></tr><tr><td></td><td>Breast carcinoma</td><td>Relapse-free survival</td><td>5</td><td>No Disease (11)</td><td>Relapse (35)</td><td>&minus;2.144</td><td>0.043</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b049">49</xref>&rsqb;</td></tr><tr><td>LY6D</td><td>Brain</td><td>Survival</td><td>3</td><td>Alive (13)</td><td>Dead (56)</td><td>&minus;3.13</td><td>0.006</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b044">44</xref>&rsqb;</td></tr><tr><td>APC</td><td>Brain</td><td>Survival</td><td>3</td><td>Alive (13)</td><td>Dead (56)</td><td>3.402</td><td>0.002</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b044">44</xref>&rsqb;</td></tr><tr><td></td><td>Brain</td><td>Survival</td><td>3</td><td>Alive (9)</td><td>Dead (20)</td><td>2.337</td><td>0.032</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b045">45</xref>&rsqb;</td></tr><tr><td>SMC1L1</td><td>Breast carcinoma</td><td>Disease-free survival</td><td>5</td><td>No disease (180)</td><td>Relapse (93)</td><td>&minus;3.843</td><td>&lt;0.001</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b048">48</xref>&rsqb;</td></tr><tr><td></td><td>Breast carcinoma</td><td>Disease-free survival</td><td>5</td><td>No disease (196)</td><td>Relapse (79)</td><td>&minus;3.374</td><td>&lt;0.001</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b046">46</xref>&rsqb;</td></tr><tr><td>IL8RB</td><td>Breast carcinoma</td><td>Disease-free survival</td><td>5</td><td>No disease (180)</td><td>Relapse (93)</td><td>2.064</td><td>0.04</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0030467-b048">48</xref>&rsqb;</td></tr></tbody></table> --><!-- <table-wrap-foot><fn id="nt401"><p><sup>a</sup><italic>p</italic>-Value indicates significance for t-test of difference in gene expression between two classes of patients.</p></fn></table-wrap-foot> --></table-wrap>
      <p><italic>ABCC1</italic> and <italic>SLC2A1</italic> are particularly attractive biomarkers
        for survival in NSCLC. The protein encoded by <italic>ABCC1</italic> is a member of the
        superfamily of ATP-binding cassette transporters. ATP-binding cassette proteins transport
        various molecules across extra- and intracellular membranes. This full transporter is a
        member of the multidrug resistance-associated protein subfamily, and it functions as a
        multispecific organic anion transporter, with oxidized glutathione, cysteinyl leukotrienes,
        and activated aflatoxin B1 as substrates. This protein also transports glucuronides and
        sulfate conjugates of steroid hormones and bile salts. ABCC1 overexpression is associated
        with DNA aneuploid carcinomatous cells in NSCLC [<xref ref-type="bibr" rid="pmed-0030467-b030">30</xref>]. SLC2A1 is a major glucose transporter, which
        is an integral membrane glycoprotein involved in transporting glucose into most cells.
        Increased glucose transport in malignant cells has been associated with increased,
        deregulated expression of glucose transporter proteins that is characterized by the
        overexpression of SLC2A1 [<xref ref-type="bibr" rid="pmed-0030467-b031">31</xref>]. Differential expression levels of SLC2A1 have been observed between
        ADC and SCC [<xref ref-type="bibr" rid="pmed-0030467-b032">32</xref>], and
        overexpression of SLC2A1 in stage I NSCLC resulted in poor survival in another experiment
          [<xref ref-type="bibr" rid="pmed-0030467-b033">33</xref>]. Thus, these
        two genes could be targets of cancer therapy and prevention.</p>
      <p>The survival-related genes identified in previous microarray studies of lung cancer
        patients failed to show consistency between studies, likely due to small patient sample
        numbers [<xref ref-type="bibr" rid="pmed-0030467-b034">34</xref>], and
        their predictive power was limited when tested in independent datasets. One solution to this
        problem is to integrate datasets from multiple studies to increase the sample size. Another
        problem is systematic biases due to different handling procedures in clinical studies,
        especially when samples/tumors are collected and processed at different institutions, using
        different microarray print batches, platforms, or array hybridization protocols. To
        integrate microarray datasets with different origins, distribution transformation methods,
        such as DWD, can be helpful. This method has been used previously to combine datasets from
        different batches into a single homogeneous dataset in head and neck SCC and breast
        carcinoma studies [<xref ref-type="bibr" rid="pmed-0030467-b035">35</xref>–<xref ref-type="bibr" rid="pmed-0030467-b038">38</xref>]. In
        our data analyses, we chose WUSM dataset as the reference batch, used the same mean and
        variance as reference, and then combined other datasets one by one. The hierarchical cluster
        analysis using the original nontransformed data classified the samples into five distinct
        groups according to data source rather than disease status (<xref ref-type="supplementary-material" rid="pmed-0030467-sg001">Figure S1</xref>A),
        demonstrating large systematic biases among the five studies. After DWD adjustment, however,
        all 197 samples from the five datasets were clustered into two sub-branches according to
        disease status rather than data source, each of which was composed of samples from all five
        datasets (<xref ref-type="supplementary-material" rid="pmed-0030467-sg001">Figure
        S1</xref>B). The batch differences disappeared; in this sense the samples from different
        datasets mixed well. <xref ref-type="supplementary-material" rid="pmed-0030467-sg004">Figure
          S4</xref> also shows the effect of DWD adjustment using datasets 1 and 3. Principal
        component directions of adjusted data are markedly different from those of the raw data. We
        also performed poolability tests to examine if these DWD-transformed gene expression data
        from different resources are poolable. The results showed that the number of
        <italic>p</italic>-values falling in the tail in our data is similar to those in simulated
        data (<xref ref-type="supplementary-material" rid="pmed-0030467-st005">Table S5</xref>).
        Therefore, the gene expression data from different resources are poolable after the DWD
        transformation, and thus can be combined for survival analysis. These results imply that the
        systematic biases were largely removed after DWD adjustment and thus the results from the
        integrated data should be robust.</p>
      <p>Time to death due to cancer varies substantially among lung cancer patients. Studying
        censored survival time may be more informative than treating it as a binary or categorical
        variable. We applied multivariate Cox proportional hazards models with bootstrap resampling
        technology to the analysis of these censored survival data from different resource.
        Kaplan-Meier analysis using gene expression profiles demonstrated a significantly worse
        overall survival for high-risk patients compared to low-risk patients (<xref ref-type="fig" rid="pmed-0030467-g002">Figure 2</xref>B), and using the 64-gene signature, we predicted
        the actual overall survival with greater than 85% accuracy. This new tool will
        help clinicians assess a patient's risk profile and to prescribe a course of treatment
        tailored to that profile. A patient whose cancer signature indicates that it is unlikely to
        metastasize would be spared the debilitating side effects of aggressive anticancer
        therapies, whereas a patient with an early but particularly aggressive tumor would be a
        candidate for aggressive treatment not usually given to early-stage patients, and thus
        experience improved survival.</p>
    </sec>
    <sec id="s5">
      <title>Supporting Information</title>
      <supplementary-material id="pmed-0030467-sg001" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pmed.0030467.sg001" xlink:type="simple">
        <label>Figure S1</label>
        <caption>
          <title>Hierarchical Clustering Analysis of Five Datasets</title>
          <p>Analyses are shown for the raw data (A) and the DWD source and batch-adjusted data (B).
            Green, dataset 1 (WUSM); purple, dataset 2 (Mayo Clinic); blue, dataset 3 (Beer et al.
              [<xref ref-type="bibr" rid="pmed-0030467-b005">5</xref>]); red,
            dataset 4 (Bhattacharjee et al. [<xref ref-type="bibr" rid="pmed-0030467-b010">10</xref>]); yellow, dataset 5 (Borczuk et al. [<xref ref-type="bibr" rid="pmed-0030467-b008">8</xref>]).</p>
          <p>(65 KB PDF)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pmed-0030467-sg002" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pmed.0030467.sg002" xlink:type="simple">
        <label>Figure S2</label>
        <caption>
          <title>Global <italic>p</italic>-Values from Tests of the Proportional Hazards Assumption
            for All Survival-Related Genes</title>
          <p>Only two of 165 tests obtained global <italic>p</italic> &lt; 0.05, indicating that
            proportional hazards models are statistically warranted for the survival analyses.</p>
          <p>(72 KB PDF)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pmed-0030467-sg003" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pmed.0030467.sg003" xlink:type="simple">
        <label>Figure S3</label>
        <caption>
          <title>The Immunostaining Images of Lung Cancer Patient Tissue Microarray</title>
          <p>The sections from short-term survival lung cancer patients are shown in box.</p>
          <p>(1.3 MB PDF)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pmed-0030467-sg004" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pmed.0030467.sg004" xlink:type="simple">
        <label>Figure S4</label>
        <caption>
          <title>Principle Component Directions</title>
          <p>Directions are given for the raw data (A) and the DWD source- and batch-adjusted data
            (B). Red, dataset 1 (WUSM); blue, dataset 3 (Beer et al. [<xref ref-type="bibr" rid="pmed-0030467-b005">5</xref>]).</p>
          <p>(513 KB PDF)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pmed-0030467-sd001" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pmed.0030467.sd001" xlink:type="simple">
        <label>Protocol S1</label>
        <caption>
          <title>Detailed Description of the Data Analyses</title>
          <p>(84 KB DOC)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pmed-0030467-st001" mimetype="application/msexcel" position="float" xlink:href="info:doi/10.1371/journal.pmed.0030467.st001" xlink:type="simple">
        <label>Table S1</label>
        <caption>
          <title>Sample Information on Datasets Used in the Meta-Analysis</title>
          <p>(73 KB XLS)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pmed-0030467-st002" mimetype="application/msexcel" position="float" xlink:href="info:doi/10.1371/journal.pmed.0030467.st002" xlink:type="simple">
        <label>Table S2</label>
        <caption>
          <title>Oligonucleotide Primers and Probes Used for RT-PCR Analysis</title>
          <p>(23 KB XLS)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pmed-0030467-st003" mimetype="application/msexcel" position="float" xlink:href="info:doi/10.1371/journal.pmed.0030467.st003" xlink:type="simple">
        <label>Table S3</label>
        <caption>
          <title>Detailed Information on Genes Related to Cancer Survival</title>
          <p>(32 KB XLS)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pmed-0030467-st004" mimetype="application/msexcel" position="float" xlink:href="info:doi/10.1371/journal.pmed.0030467.st004" xlink:type="simple">
        <label>Table S4</label>
        <caption>
          <title>Partial Cox Regression Classification of 197 stage I NSCLC patient using 64
            Survival-Related Genes</title>
          <p>(32 KB XLS)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pmed-0030467-st005" mimetype="application/msexcel" position="float" xlink:href="info:doi/10.1371/journal.pmed.0030467.st005" xlink:type="simple">
        <label>Table S5</label>
        <caption>
          <title>Comparison of the Distribution of <italic>p</italic>-Values from Poolability Tests
            in the Real and Simulated Data</title>
          <p>(15 KB XLS)</p>
        </caption>
      </supplementary-material>
      <sec id="s5a">
        <title>Accession Numbers</title>
        <p>Accession numbers for genes related to cancer survival in <xref ref-type="supplementary-material" rid="pmed-0030467-st003">Table S3</xref> can be found
          in Nucleotide (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Nucleotide" xlink:type="simple">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Nucleotide</ext-link>). The
          Gene Expression Omnibus (GEO [<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo" xlink:type="simple">http://www.ncbi.nlm.nih.gov/geo</ext-link>]) accession number for microarray
          data from this study is GSE6253.</p>
      </sec>
    </sec>
  </body>
  <back>
    <ack>
      <p>We thank Dr. David Beer at University of Michigan, Dr. Arindam Bhattacharjee at Harvard
        University, and Dr. Charles Powell at Columbia University for releasing microarray data.
        Some of the lung cancer tissues were procured from the tumor tissue bank at Washington
        University School of Medicine.</p>
    </ack>
    
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>ADC</term>
          <def>
            <p>adenocarcinoma</p>
          </def>
        </def-item>
        <def-item>
          <term>DWD</term>
          <def>
            <p>distance-weighted discrimination</p>
          </def>
        </def-item>
        <def-item>
          <term>NSCLC</term>
          <def>
            <p>non-small cell lung cancer</p>
          </def>
        </def-item>
        <def-item>
          <term>QRT-PCR</term>
          <def>
            <p>quantitative real-time polymerase chain reaction</p>
          </def>
        </def-item>
        <def-item>
          <term>SCC</term>
          <def>
            <p>squamous cell carcinoma</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <ref-list>
      <title>References</title>
      <ref id="pmed-0030467-b001">
        <label>1</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Spiro</surname><given-names>SG</given-names></name><name name-style="western"><surname>Silvestri</surname><given-names>GA</given-names></name></person-group>
          <year>2005</year>
          <article-title>One hundred years of lung cancer.</article-title>
          <source>Am J Respir Crit Care Med</source>
          <volume>172</volume>
          <fpage>523</fpage>
          <lpage>529</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b002">
        <label>2</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Bach</surname><given-names>PB</given-names></name><name name-style="western"><surname>Kelley</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Tate</surname><given-names>RC</given-names></name><name name-style="western"><surname>McCrory</surname><given-names>DC</given-names></name></person-group>
          <year>2003</year>
          <article-title>Screening for lung cancer: A review of the current literature.</article-title>
          <source>Chest</source>
          <volume>123</volume>
          <fpage>72S</fpage>
          <lpage>82S</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b003">
        <label>3</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Mountain</surname><given-names>CF</given-names></name><name name-style="western"><surname>Dresler</surname><given-names>CM</given-names></name></person-group>
          <year>1997</year>
          <article-title>Regional lymph node classification for lung cancer staging.</article-title>
          <source>Chest</source>
          <volume>111</volume>
          <fpage>1718</fpage>
          <lpage>1723</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b004">
        <label>4</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>El-Sherif</surname><given-names>A</given-names></name><name name-style="western"><surname>Luketich</surname><given-names>JD</given-names></name><name name-style="western"><surname>Landreneau</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Fernando</surname><given-names>HC</given-names></name></person-group>
          <year>2005</year>
          <article-title>New therapeutic approaches for early stage non-small cell lung cancer.</article-title>
          <source>Surg Oncol</source>
          <volume>14</volume>
          <fpage>27</fpage>
          <lpage>32</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b005">
        <label>5</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Beer</surname><given-names>DG</given-names></name><name name-style="western"><surname>Kardia</surname><given-names>SL</given-names></name><name name-style="western"><surname>Huang</surname><given-names>CC</given-names></name><name name-style="western"><surname>Giordano</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Levin</surname><given-names>AM</given-names></name><etal/></person-group>
          <year>2002</year>
          <article-title>Gene-expression profiles predict survival of patients with lung
            adenocarcinoma.</article-title>
          <source>Nat Med</source>
          <volume>8</volume>
          <fpage>816</fpage>
          <lpage>824</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b006">
        <label>6</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>P</given-names></name><name name-style="western"><surname>Aubry</surname><given-names>MC</given-names></name><name name-style="western"><surname>Kosari</surname><given-names>F</given-names></name><name name-style="western"><surname>Endo</surname><given-names>C</given-names></name><etal/></person-group>
          <year>2004</year>
          <article-title>Can gene expression profiling predict survival for patients with squamous
            cell carcinoma of the lung?</article-title>
          <source>Mol Cancer</source>
          <volume>3</volume>
          <fpage>35</fpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b007">
        <label>7</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Wigle</surname><given-names>DA</given-names></name><name name-style="western"><surname>Jurisica</surname><given-names>I</given-names></name><name name-style="western"><surname>Radulovich</surname><given-names>N</given-names></name><name name-style="western"><surname>Pintilie</surname><given-names>M</given-names></name><name name-style="western"><surname>Rossant</surname><given-names>J</given-names></name><etal/></person-group>
          <year>2002</year>
          <article-title>Molecular profiling of non-small cell lung cancer and correlation with
            disease-free survival.</article-title>
          <source>Cancer Res</source>
          <volume>62</volume>
          <fpage>3005</fpage>
          <lpage>3008</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b008">
        <label>8</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Borczuk</surname><given-names>AC</given-names></name><name name-style="western"><surname>Shah</surname><given-names>L</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>GD</given-names></name><name name-style="western"><surname>Walter</surname><given-names>KL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group>
          <year>2004</year>
          <article-title>Molecular signatures in biopsy specimens of lung cancer.</article-title>
          <source>Am J Respir Crit Care Med</source>
          <volume>170</volume>
          <fpage>167</fpage>
          <lpage>174</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b009">
        <label>9</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Irizarry</surname><given-names>RA</given-names></name><name name-style="western"><surname>Bolstad</surname><given-names>BM</given-names></name><name name-style="western"><surname>Collin</surname><given-names>F</given-names></name><name name-style="western"><surname>Cope</surname><given-names>LM</given-names></name><name name-style="western"><surname>Hobbs</surname><given-names>B</given-names></name><etal/></person-group>
          <year>2003</year>
          <article-title>Summaries of Affymetrix GeneChip probe level data.</article-title>
          <source>Nucleic Acids Res</source>
          <volume>31</volume>
          <fpage>e15</fpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b010">
        <label>10</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Bhattacharjee</surname><given-names>A</given-names></name><name name-style="western"><surname>Richards</surname><given-names>WG</given-names></name><name name-style="western"><surname>Staunton</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Monti</surname><given-names>S</given-names></name><etal/></person-group>
          <year>2001</year>
          <article-title>Classification of human lung carcinomas by mRNA expression profiling
            reveals distinct adenocarcinoma subclasses.</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <volume>98</volume>
          <fpage>13790</fpage>
          <lpage>13795</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b011">
        <label>11</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Bild</surname><given-names>AH</given-names></name><name name-style="western"><surname>Yao</surname><given-names>G</given-names></name><name name-style="western"><surname>Chang</surname><given-names>JT</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Potti</surname><given-names>A</given-names></name><etal/></person-group>
          <year>2006</year>
          <article-title>Oncogenic pathway signatures in human cancers as a guide to targeted
            therapies.</article-title>
          <source>Nature</source>
          <volume>439</volume>
          <fpage>353</fpage>
          <lpage>357</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b012">
        <label>12</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name><name name-style="western"><surname>Loraine</surname><given-names>AE</given-names></name><name name-style="western"><surname>Shigeta</surname><given-names>R</given-names></name><name name-style="western"><surname>Cline</surname><given-names>M</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>J</given-names></name><etal/></person-group>
          <year>2003</year>
          <article-title>NetAffx: Affymetrix probesets and annotations.</article-title>
          <source>Nucleic Acids Res</source>
          <volume>31</volume>
          <fpage>82</fpage>
          <lpage>86</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b013">
        <label>13</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Benito</surname><given-names>M</given-names></name><name name-style="western"><surname>Parker</surname><given-names>J</given-names></name><name name-style="western"><surname>Du</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>D</given-names></name><etal/></person-group>
          <year>2004</year>
          <article-title>Adjustment of systematic microarray data biases.</article-title>
          <source>Bioinformatics</source>
          <volume>20</volume>
          <fpage>105</fpage>
          <lpage>114</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b014">
        <label>14</label>
        <element-citation publication-type="other" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Baltagi</surname><given-names>BH</given-names></name></person-group>
          <year>2005</year>
          <source>Econometric analysis of panel data. 3rd Ed</source>
          <publisher-loc>Hoboken, New Jersey</publisher-loc>
          <publisher-name>John Wiley and Sons</publisher-name>
          <fpage>314</fpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b015">
        <label>15</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Gui</surname><given-names>J</given-names></name></person-group>
          <year>2004</year>
          <article-title>Partial Cox regression analysis for high-dimensional microarray gene
            expression data.</article-title>
          <source>Bioinformatics</source>
          <volume>20</volume>
          <issue>Suppl 1</issue>
          <fpage>I208</fpage>
          <lpage>I215</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b016">
        <label>16</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Ihaka</surname><given-names>R</given-names></name><name name-style="western"><surname>Gentleman</surname><given-names>R</given-names></name></person-group>
          <year>1996</year>
          <article-title>R: A language for data analysis and graphics.</article-title>
          <source>J Comput Graph Statist</source>
          <volume>5</volume>
          <fpage>299</fpage>
          <lpage>314</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b017">
        <label>17</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Chaparro</surname><given-names>J</given-names></name><name name-style="western"><surname>Reeds</surname><given-names>DN</given-names></name><name name-style="western"><surname>Wen</surname><given-names>W</given-names></name><name name-style="western"><surname>Xueping</surname><given-names>E</given-names></name><name name-style="western"><surname>Klein</surname><given-names>S</given-names></name><etal/></person-group>
          <year>2005</year>
          <article-title>Alterations in thigh subcutaneous adipose tissue gene expression in
            protease inhibitor-based highly active antiretroviral therapy.</article-title>
          <source>Metabolism</source>
          <volume>54</volume>
          <fpage>561</fpage>
          <lpage>567</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b018">
        <label>18</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Livak</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group>
          <year>2001</year>
          <article-title>Analysis of relative gene expression data using real-time quantitative PCR
            and the 2(–ΔΔC<sub>T</sub>) method.</article-title>
          <source>Methods</source>
          <volume>25</volume>
          <fpage>402</fpage>
          <lpage>408</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b019">
        <label>19</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Brabender</surname><given-names>J</given-names></name><name name-style="western"><surname>Usadel</surname><given-names>H</given-names></name><name name-style="western"><surname>Danenberg</surname><given-names>KD</given-names></name><name name-style="western"><surname>Metzger</surname><given-names>R</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>PM</given-names></name><etal/></person-group>
          <year>2001</year>
          <article-title>Adenomatous polyposis coli gene promoter hypermethylation in non-small cell
            lung cancer is associated with survival.</article-title>
          <source>Oncogene</source>
          <volume>20</volume>
          <fpage>3528</fpage>
          <lpage>3532</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b020">
        <label>20</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Mattern</surname><given-names>J</given-names></name><name name-style="western"><surname>Koomagi</surname><given-names>R</given-names></name><name name-style="western"><surname>Volm</surname><given-names>M</given-names></name></person-group>
          <year>2002</year>
          <article-title>Characteristics of long-term survivors of untreated lung cancer.</article-title>
          <source>Lung Cancer</source>
          <volume>36</volume>
          <fpage>277</fpage>
          <lpage>282</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b021">
        <label>21</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Schaich</surname><given-names>M</given-names></name><name name-style="western"><surname>Soucek</surname><given-names>S</given-names></name><name name-style="western"><surname>Thiede</surname><given-names>C</given-names></name><name name-style="western"><surname>Ehninger</surname><given-names>G</given-names></name><name name-style="western"><surname>Illmer</surname><given-names>T</given-names></name></person-group>
          <year>2005</year>
          <article-title>MDR1 and MRP1 gene expression are independent predictors for treatment
            outcome in adult acute myeloid leukaemia.</article-title>
          <source>Br J Haematol</source>
          <volume>128</volume>
          <fpage>324</fpage>
          <lpage>332</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b022">
        <label>22</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Drexler</surname><given-names>HG</given-names></name><name name-style="western"><surname>Quentmeier</surname><given-names>H</given-names></name></person-group>
          <year>2004</year>
          <article-title>FLT3: Receptor and ligand.</article-title>
          <source>Growth Factors</source>
          <volume>22</volume>
          <fpage>71</fpage>
          <lpage>73</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b023">
        <label>23</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>WF</given-names></name><name name-style="western"><surname>Lin</surname><given-names>RX</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><etal/></person-group>
          <year>2005</year>
          <article-title>Identification of differentially expressed genes contributing to
            radioresistance in lung cancer cells using microarray analysis.</article-title>
          <source>Radiat Res</source>
          <volume>164</volume>
          <fpage>27</fpage>
          <lpage>35</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b024">
        <label>24</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>SM</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>TT</given-names></name></person-group>
          <year>2005</year>
          <article-title>Immunoreactivity of CD10 and inhibin alpha in differentiating
            hemangioblastoma of central nervous system from metastatic clear cell renal cell
            carcinoma.</article-title>
          <source>Mod Pathol</source>
          <volume>18</volume>
          <fpage>788</fpage>
          <lpage>794</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b025">
        <label>25</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Shivapurkar</surname><given-names>N</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>J</given-names></name><name name-style="western"><surname>Matta</surname><given-names>H</given-names></name><name name-style="western"><surname>Sathyanarayana</surname><given-names>UG</given-names></name><name name-style="western"><surname>Huang</surname><given-names>CX</given-names></name><etal/></person-group>
          <year>2002</year>
          <article-title>Loss of expression of death-inducing signaling complex (DISC) components in
            lung cancer cell lines and the influence of MYC amplification.</article-title>
          <source>Oncogene</source>
          <volume>21</volume>
          <fpage>8510</fpage>
          <lpage>8514</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b026">
        <label>26</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Eberhart</surname><given-names>CG</given-names></name><name name-style="western"><surname>Kratz</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Summers</surname><given-names>K</given-names></name><name name-style="western"><surname>Stearns</surname><given-names>D</given-names></name><etal/></person-group>
          <year>2004</year>
          <article-title>Histopathological and molecular prognostic markers in medulloblastoma:
            c-Myc, N-myc, TrkC, and anaplasia.</article-title>
          <source>J Neuropathol Exp Neurol</source>
          <volume>63</volume>
          <fpage>441</fpage>
          <lpage>449</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b027">
        <label>27</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Baldus</surname><given-names>SE</given-names></name><name name-style="western"><surname>Monig</surname><given-names>SP</given-names></name><name name-style="western"><surname>Huxel</surname><given-names>S</given-names></name><name name-style="western"><surname>Landsberg</surname><given-names>S</given-names></name><name name-style="western"><surname>Hanisch</surname><given-names>FG</given-names></name><etal/></person-group>
          <year>2004</year>
          <article-title>MUC1 and nuclear beta-catenin are coexpressed at the invasion front of
            colorectal carcinomas and are both correlated with tumor prognosis.</article-title>
          <source>Clin Cancer Res</source>
          <volume>10</volume>
          <fpage>2790</fpage>
          <lpage>2796</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b028">
        <label>28</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Garber</surname><given-names>ME</given-names></name><name name-style="western"><surname>Troyanskaya</surname><given-names>OG</given-names></name><name name-style="western"><surname>Schluens</surname><given-names>K</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>S</given-names></name><name name-style="western"><surname>Thaesler</surname><given-names>Z</given-names></name><etal/></person-group>
          <year>2001</year>
          <article-title>Diversity of gene expression in adenocarcinoma of the lung.</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <volume>98</volume>
          <fpage>13784</fpage>
          <lpage>13789</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b029">
        <label>29</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Roukos</surname><given-names>DH</given-names></name><name name-style="western"><surname>Kappas</surname><given-names>AM</given-names></name></person-group>
          <year>2005</year>
          <article-title>Perspectives in the treatment of gastric cancer.</article-title>
          <source>Nat Clin Pract Oncol</source>
          <volume>2</volume>
          <fpage>98</fpage>
          <lpage>107</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b030">
        <label>30</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Doubre</surname><given-names>H</given-names></name><name name-style="western"><surname>Cesari</surname><given-names>D</given-names></name><name name-style="western"><surname>Mairovitz</surname><given-names>A</given-names></name><name name-style="western"><surname>Benac</surname><given-names>C</given-names></name><name name-style="western"><surname>Chantot-Bastaraud</surname><given-names>S</given-names></name><etal/></person-group>
          <year>2005</year>
          <article-title>Multidrug resistance-associated protein (MRP1) is overexpressed in DNA
            aneuploid carcinomatous cells in non-small cell lung cancer (NSCLC).</article-title>
          <source>Int J Cancer</source>
          <volume>113</volume>
          <fpage>568</fpage>
          <lpage>574</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b031">
        <label>31</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Macheda</surname><given-names>ML</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>S</given-names></name><name name-style="western"><surname>Best</surname><given-names>JD</given-names></name></person-group>
          <year>2005</year>
          <article-title>Molecular and cellular regulation of glucose transporter (GLUT) proteins in
            cancer.</article-title>
          <source>J Cell Physiol</source>
          <volume>202</volume>
          <fpage>654</fpage>
          <lpage>662</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b032">
        <label>32</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Yamagata</surname><given-names>N</given-names></name><name name-style="western"><surname>Shyr</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yanagisawa</surname><given-names>K</given-names></name><name name-style="western"><surname>Edgerton</surname><given-names>M</given-names></name><name name-style="western"><surname>Dang</surname><given-names>TP</given-names></name><etal/></person-group>
          <year>2003</year>
          <article-title>A training-testing approach to the molecular classification of resected
            non-small cell lung cancer.</article-title>
          <source>Clin Cancer Res</source>
          <volume>9</volume>
          <fpage>4695</fpage>
          <lpage>4704</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b033">
        <label>33</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Younes</surname><given-names>M</given-names></name><name name-style="western"><surname>Brown</surname><given-names>RW</given-names></name><name name-style="western"><surname>Stephenson</surname><given-names>M</given-names></name><name name-style="western"><surname>Gondo</surname><given-names>M</given-names></name><name name-style="western"><surname>Cagle</surname><given-names>PT</given-names></name></person-group>
          <year>1997</year>
          <article-title>Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma
            is associated with poor survival.</article-title>
          <source>Cancer</source>
          <volume>80</volume>
          <fpage>1046</fpage>
          <lpage>1051</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b034">
        <label>34</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><name name-style="western"><surname>Tan</surname><given-names>AC</given-names></name><name name-style="western"><surname>Naiman</surname><given-names>DQ</given-names></name><name name-style="western"><surname>Geman</surname><given-names>D</given-names></name><name name-style="western"><surname>Winslow</surname><given-names>RL</given-names></name></person-group>
          <year>2005</year>
          <article-title>Robust prostate cancer marker genes emerge from direct integration of
            inter-study microarray data.</article-title>
          <source>Bioinformatics</source>
          <volume>21</volume>
          <fpage>3905</fpage>
          <lpage>3911</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b035">
        <label>35</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>CH</given-names></name><name name-style="western"><surname>Parker</surname><given-names>JS</given-names></name><name name-style="western"><surname>Karaca</surname><given-names>G</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Funkhouser</surname><given-names>WK</given-names></name><etal/></person-group>
          <year>2004</year>
          <article-title>Molecular classification of head and neck squamous cell carcinomas using
            patterns of gene expression.</article-title>
          <source>Cancer Cell</source>
          <volume>5</volume>
          <fpage>489</fpage>
          <lpage>500</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b036">
        <label>36</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Fan</surname><given-names>C</given-names></name><name name-style="western"><surname>Oh</surname><given-names>DS</given-names></name><name name-style="western"><surname>Marron</surname><given-names>JS</given-names></name><name name-style="western"><surname>He</surname><given-names>X</given-names></name><etal/></person-group>
          <year>2006</year>
          <article-title>The molecular portraits of breast tumors are conserved across microarray
            platforms.</article-title>
          <source>BMC Genomics</source>
          <volume>7</volume>
          <fpage>96</fpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b037">
        <label>37</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>DS</given-names></name><name name-style="western"><surname>Troester</surname><given-names>MA</given-names></name><name name-style="western"><surname>Usary</surname><given-names>J</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z</given-names></name><name name-style="western"><surname>He</surname><given-names>X</given-names></name><etal/></person-group>
          <year>2006</year>
          <article-title>Estrogen-regulated genes predict survival in hormone receptor-positive
            breast cancers.</article-title>
          <source>J Clin Oncol</source>
          <volume>24</volume>
          <fpage>1656</fpage>
          <lpage>1664</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b038">
        <label>38</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Perreard</surname><given-names>L</given-names></name><name name-style="western"><surname>Fan</surname><given-names>C</given-names></name><name name-style="western"><surname>Quackenbush</surname><given-names>JF</given-names></name><name name-style="western"><surname>Mullins</surname><given-names>M</given-names></name><name name-style="western"><surname>Gauthier</surname><given-names>NP</given-names></name><etal/></person-group>
          <year>2006</year>
          <article-title>Classification and risk stratification of invasive breast carcinomas using
            a real-time quantitative RT-PCR assay.</article-title>
          <source>Breast Cancer Res</source>
          <volume>8</volume>
          <fpage>R23</fpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b039">
        <label>39</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Yilmaz</surname><given-names>A</given-names></name><name name-style="western"><surname>Savas</surname><given-names>I</given-names></name><name name-style="western"><surname>Dizbay Sak</surname><given-names>S</given-names></name><name name-style="western"><surname>Gungor</surname><given-names>A</given-names></name><name name-style="western"><surname>Kaya</surname><given-names>A</given-names></name><etal/></person-group>
          <year>2005</year>
          <article-title>Distribution of Bcl-2 gene expression and its prognostic value in non-small
            cell lung cancer.</article-title>
          <source>Tuberk Toraks</source>
          <volume>53</volume>
          <fpage>323</fpage>
          <lpage>329</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b040">
        <label>40</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>B</given-names></name><name name-style="western"><surname>Paesmans</surname><given-names>M</given-names></name><name name-style="western"><surname>Berghmans</surname><given-names>T</given-names></name><name name-style="western"><surname>Branle</surname><given-names>F</given-names></name><name name-style="western"><surname>Ghisdal</surname><given-names>L</given-names></name><etal/></person-group>
          <year>2003</year>
          <article-title>Role of Bcl-2 as a prognostic factor for survival in lung cancer: A
            systematic review of the literature with meta-analysis.</article-title>
          <source>Br J Cancer</source>
          <volume>89</volume>
          <fpage>55</fpage>
          <lpage>64</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b041">
        <label>41</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>M</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ohira</surname><given-names>M</given-names></name><name name-style="western"><surname>Ando</surname><given-names>S</given-names></name><etal/></person-group>
          <year>2005</year>
          <article-title>Aberrant methylation of FBN2 in human non-small cell lung cancer.</article-title>
          <source>Lung Cancer</source>
          <volume>50</volume>
          <fpage>43</fpage>
          <lpage>49</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b042">
        <label>42</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Minami</surname><given-names>K</given-names></name><name name-style="western"><surname>Saito</surname><given-names>Y</given-names></name><name name-style="western"><surname>Imamura</surname><given-names>H</given-names></name><name name-style="western"><surname>Okamura</surname><given-names>A</given-names></name></person-group>
          <year>2002</year>
          <article-title>Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I
            adenocarcinoma of the lung.</article-title>
          <source>Lung Cancer</source>
          <volume>38</volume>
          <fpage>51</fpage>
          <lpage>57</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b043">
        <label>43</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>P</given-names></name><name name-style="western"><surname>Ebbert</surname><given-names>JO</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Z</given-names></name><name name-style="western"><surname>Weinshilboum</surname><given-names>RM</given-names></name></person-group>
          <year>2006</year>
          <article-title>Role of the glutathione metabolic pathway in lung cancer treatment and
            prognosis: A review.</article-title>
          <source>J Clin Oncol</source>
          <volume>24</volume>
          <fpage>1761</fpage>
          <lpage>1769</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b044">
        <label>44</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Freije</surname><given-names>WA</given-names></name><name name-style="western"><surname>Castro-Vargas</surname><given-names>FE</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Horvath</surname><given-names>S</given-names></name><name name-style="western"><surname>Cloughesy</surname><given-names>T</given-names></name><etal/></person-group>
          <year>2004</year>
          <article-title>Gene expression profiling of gliomas strongly predicts survival.</article-title>
          <source>Cancer Res</source>
          <volume>64</volume>
          <fpage>6503</fpage>
          <lpage>6510</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b045">
        <label>45</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Shai</surname><given-names>R</given-names></name><name name-style="western"><surname>Shi</surname><given-names>T</given-names></name><name name-style="western"><surname>Kremen</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Horvath</surname><given-names>S</given-names></name><name name-style="western"><surname>Liau</surname><given-names>LM</given-names></name><etal/></person-group>
          <year>2003</year>
          <article-title>Gene expression profiling identifies molecular subtypes of gliomas.</article-title>
          <source>Oncogene</source>
          <volume>22</volume>
          <fpage>4918</fpage>
          <lpage>4923</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b046">
        <label>46</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>van de Vijver</surname><given-names>MJ</given-names></name><name name-style="western"><surname>He</surname><given-names>YD</given-names></name><name name-style="western"><surname>van't Veer</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Dai</surname><given-names>H</given-names></name><name name-style="western"><surname>Hart</surname><given-names>AA</given-names></name><etal/></person-group>
          <year>2002</year>
          <article-title>A gene-expression signature as a predictor of survival in breast cancer.</article-title>
          <source>N Engl J Med</source>
          <volume>347</volume>
          <fpage>1999</fpage>
          <lpage>2009</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b047">
        <label>47</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Leung</surname><given-names>SY</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>ST</given-names></name><name name-style="western"><surname>Chu</surname><given-names>KM</given-names></name><name name-style="western"><surname>Ji</surname><given-names>J</given-names></name><etal/></person-group>
          <year>2003</year>
          <article-title>Variation in gene expression patterns in human gastric cancers.</article-title>
          <source>Mol Biol Cell</source>
          <volume>14</volume>
          <fpage>3208</fpage>
          <lpage>3215</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b048">
        <label>48</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Klijn</surname><given-names>JG</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sieuwerts</surname><given-names>AM</given-names></name><name name-style="western"><surname>Look</surname><given-names>MP</given-names></name><etal/></person-group>
          <year>2005</year>
          <article-title>Gene-expression profiles to predict distant metastasis of
            lymph-node-negative primary breast cancer.</article-title>
          <source>Lancet</source>
          <volume>365</volume>
          <fpage>671</fpage>
          <lpage>679</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b049">
        <label>49</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Sorlie</surname><given-names>T</given-names></name><name name-style="western"><surname>Perou</surname><given-names>CM</given-names></name><name name-style="western"><surname>Tibshirani</surname><given-names>R</given-names></name><name name-style="western"><surname>Aas</surname><given-names>T</given-names></name><name name-style="western"><surname>Geisler</surname><given-names>S</given-names></name><etal/></person-group>
          <year>2001</year>
          <article-title>Gene expression patterns of breast carcinomas distinguish tumor subclasses
            with clinical implications.</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <volume>98</volume>
          <fpage>10869</fpage>
          <lpage>10874</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b050">
        <label>50</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>van 't Veer</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Dai</surname><given-names>H</given-names></name><name name-style="western"><surname>van de Vijver</surname><given-names>MJ</given-names></name><name name-style="western"><surname>He</surname><given-names>YD</given-names></name><name name-style="western"><surname>Hart</surname><given-names>AA</given-names></name><etal/></person-group>
          <year>2002</year>
          <article-title>Gene expression profiling predicts clinical outcome of breast cancer.</article-title>
          <source>Nature</source>
          <volume>415</volume>
          <fpage>530</fpage>
          <lpage>536</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b051">
        <label>51</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Pomeroy</surname><given-names>SL</given-names></name><name name-style="western"><surname>Tamayo</surname><given-names>P</given-names></name><name name-style="western"><surname>Gaasenbeek</surname><given-names>M</given-names></name><name name-style="western"><surname>Sturla</surname><given-names>LM</given-names></name><name name-style="western"><surname>Angelo</surname><given-names>M</given-names></name><etal/></person-group>
          <year>2002</year>
          <article-title>Prediction of central nervous system embryonal tumour outcome based on gene
            expression.</article-title>
          <source>Nature</source>
          <volume>415</volume>
          <fpage>436</fpage>
          <lpage>442</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b052">
        <label>52</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Sotiriou</surname><given-names>C</given-names></name><name name-style="western"><surname>Neo</surname><given-names>SY</given-names></name><name name-style="western"><surname>McShane</surname><given-names>LM</given-names></name><name name-style="western"><surname>Korn</surname><given-names>EL</given-names></name><name name-style="western"><surname>Long</surname><given-names>PM</given-names></name><etal/></person-group>
          <year>2003</year>
          <article-title>Breast cancer classification and prognosis based on gene expression
            profiles from a population-based study.</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <volume>100</volume>
          <fpage>10393</fpage>
          <lpage>10398</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b053">
        <label>53</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Vasselli</surname><given-names>JR</given-names></name><name name-style="western"><surname>Shih</surname><given-names>JH</given-names></name><name name-style="western"><surname>Iyengar</surname><given-names>SR</given-names></name><name name-style="western"><surname>Maranchie</surname><given-names>J</given-names></name><name name-style="western"><surname>Riss</surname><given-names>J</given-names></name><etal/></person-group>
          <year>2003</year>
          <article-title>Predicting survival in patients with metastatic kidney cancer by
            gene-expression profiling in the primary tumor.</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <volume>100</volume>
          <fpage>6958</fpage>
          <lpage>6963</lpage>
        </element-citation>
      </ref>
      <ref id="pmed-0030467-b054">
        <label>54</label>
        <element-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author"><name name-style="western"><surname>Rosenwald</surname><given-names>A</given-names></name><name name-style="western"><surname>Wright</surname><given-names>G</given-names></name><name name-style="western"><surname>Chan</surname><given-names>WC</given-names></name><name name-style="western"><surname>Connors</surname><given-names>JM</given-names></name><name name-style="western"><surname>Campo</surname><given-names>E</given-names></name><etal/></person-group>
          <year>2002</year>
          <article-title>The use of molecular profiling to predict survival after chemotherapy for
            diffuse large-B-cell lymphoma.</article-title>
          <source>N Engl J Med</source>
          <volume>346</volume>
          <fpage>1937</fpage>
          <lpage>1947</lpage>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>